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ABSTRACT 
Pharmacological and Behavioral Treatments for 
Migraine Headaches: A Meta-Analytic Review 
by 
Kristi Lowe Stewart , Doctor of Philosophy 
Utah State University, 2004 
Major Professor: Dr. Kevin Masters 
Department: Psychology 
Ill 
Migraine headache is a painful and often serious problem in the United States . 
There are many prophylactic pharmacological and nonpharmacological treatments 
available for migraine headaches . However , choosing between them can be difficult for 
individuals and treatment providers alike. The primary literature regarding the 
effectiveness of pharmacological and nonpharmacological treatments is quite dense. More 
than 191 primary studies were identified as providing information about the effectiveness 
of one or more treatments for migraine headaches. Of these, 82 articles were retained for 
meta-analyses on six prophylactic treatments for migraine: propranolol, flunarizine, 
divalproex sodium, thermal biofeedback, relaxation treatments, and combined treatments. 
These results suggest that all of the treatments examined have very similar treatment effect 
sizes. Effect sizes for the reduction of migraine were found to be between .60 and . 75 for 
all treatments. Results suggest that selection of treatment for migraine must be based on 
more than treatment effectiveness rates alone. 
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CHAPTER I 
PROBLEM STATEMENT 
Recurrent headaches are a problem for millions of men and women (Goldstien & 
Chen, 1982). One type of headache, the migraine, is a disabling syndrome resulting in 
significant life impairment (Unruh, 1996). There are two categories of treatments for 
migraine headaches . The first, pharmacological treatments, encompasses several classes of 
agents that are used in the treatment of headache pain including beta-adrenergic blockers, 
calcium channel blockers, and anticonvulsants (Solomon , 1995). The second category of 
treatments for migraine headaches are nonpharmacological. These include thermal and 
electromyograph (EMG) biofeedback , relaxation training, and cognitive techniques 
(Capobianco , Cheshire, & Campell, 1996). 
The primary literature regarding the effectiveness of pharmacological and 
nonpharmacological treatments is quite dense. More than 191 primary studies were 
identified as providing information about the effectiveness of one or more treatments for 
migraine headaches. A majority of these primary studies ( approximately 65%) compared 
their active treatment to a placebo or control group. Of those that did compare to other 
active treatments only three compared pharmacological and nonpharmacological 
treatments in the same study. While control group research comparisons give valuable 
information regarding whether the treatments are better than no treatment, this type of 
research design does little to inform about comparative effectiveness. As a result, there are 
at least 16 different categories of treatments with some empirical evidence supporting their 
use, but little data indicating which are the "better" treatments. Obviously, sorting through 
this amount of information arrd selecting the most effective treatment can be 
overwhelming. 
2 
Attempts have been made to synthes12e the effectiveness literature for migraine 
headaches through reviews. However, most of the existing reviews narrowly focus on 
either pharmacological or nonpharmacological treatments. There are two existing reviews 
that evaluated both pharmacological and nonpharmacological treatments for migraine 
headaches in adult populations (Holroyd & Penzien , 1990; Duke University and the 
Center for Clinical Health Policy Research, 1999a, 1999b) . The first (Holroyd & Penzien, 
1990) examined 73 primary studies , however, it examined only one pharmacological 
treatment (Propranonol) and two nonpharmacological treatments (relaxation and 
relaxation/biofeedback). Statistical methods (percent improvement) used in this meta-
analysis are unfocused estimations of effect and are not standardized. In addition, since the 
Holroyd review (which collected data through 1989), there have been several new studies 
published that examine the effectiveness of treatments for migraine headaches. 
The second review consisted of two sections of review developed by the Agency 
for Health Care Policy and Research (Duke University, Center for Clinical Health and 
Policy Research , 1999a, 1999b). This review was published after the proposal date of the 
current project and it mirrors many of the current authors intentions. The first part of the 
Duke University (1999a) review synthesized the data for behavioral and physical 
treatments for migraine. This methodologically sophisticated review was excellent in most 
aspects. The second part of the review (1999b) synthesized the data for prophylactic 
pharmacological agents for migraine. The review only included randomized controlled 
3 
trials of pharmacological, psychological, behavioral and physical (e.g., acupuncture) 
treatments. However, this meta-analysis did not compare the findings between 
pharmacological and nonpharmacological groups. Of interest was the authors ' choice in 
this review to include the percent improvement measure in the nonpharmacological data 
and not in the pharmacological data. This was curious given their emphasis on consistency 
of evaluation methods across domains. In addition, the results have not been published 
(likely due to length and complexity) outside of the National Technical Information 
Service (NTIS). Therefore , the area of migraine headaches is without an easily accessible 
comprehensive review of the primary research literature . 
The lack of synthesis of the literature between two supposedly empirically 
supported categories of treatment made it difficult to determine which, if any, of the 
treatments were most effective. It is important to understand how pharmacological and 
nonpharmacological treatments compare to one another so that practitioners and 
consumers can make informed choices. Therefore , a new meta-analytic review needed to 
be conducted that integrated the data from both pharmacological and nonpharmacological 
research. A single integrative review of the effectiveness findings for migraine will serve as 
a valuable resource for information regarding recurrent headaches and will fill a void that 
exists in the research literature. This project endeavored to fill this void by conducting 
meta-analyses on six prophylactic treatments for migraine and comparing them to one 
another. 
4 
CHAPTER II 
REVIEW OF THE LITERATURE 
Introduction 
This review of the literature begins with a brief overview of migraine headaches, 
other related recurrent headaches syndromes, and their treatments. Recurrent headaches 
are a problem for millions of Americans and many treatment options are available. 
However, this review of migraine headaches and the two treatment categories available 
(pharmacological and nonpharmacological) will illustrate that the sheer number of 
available treatment choices can create decision-making difficulties for professionals and 
consumers alike. It is suggested that what is needed in the area of migraine headache 
treatment research is a synthesis of the data and a comparison of effectiveness rates across 
categories. One option to meet this need, a meta-analysis, is presented. Previous reviews 
on the topic are then explored to examine where previous meta-analyses have succeeded 
and failed. In addition, previous reviews are examined to develop guidelines for a 
proposed meta-analytic review. 
Recurrent Headache Syndromes 
While most people experience mild headaches from time to time, millions of people 
each year are affected by disabling headaches (Holroyd & French, 1995). New cases of 
disabling recurrent headaches are estimated to occur at nearly two million per year; 
making recurrent headaches a serious health problem in the United States (Goldstein & 
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Chen, 1982). Recurrent headaches are not a homogenous group of symptoms. Rather, a 
recent classification system identified 12 diagnostic categories with 145 subcategories of 
headaches (Headache Classification Committee of the International Headache Society 
[IHS], 1988). The 12 major diagnostic categories can be broken into three basic types of 
headaches: migraine, tension, and mixed type. Each type of headache is associated with 
specific symptom profiles. These profiles help make headache syndromes distinct from one 
another. This review is primarily interested in exploring migraine headache syndrome. 
Therefore, this section presents the symptom profile, the prevalence, and the etiology of 
migraine headache syndrome. It is necessary, however, to establish a general 
understanding of the full range of other recurrent headache syndromes (tension and mixed) 
to evaluate how migraine headaches relate to these other syndromes. Thus, tension 
headache and mixed-type headache will also be briefly described in this section. Then in 
the following section, treatment modalities for migraine headache syndrome will be 
explored. 
Migraine Headaches 
Migraine headaches are characterized by severe periodic pulsating headaches 
which can range in duration from a few minutes to three days. Migraines have unilateral 
locations ( occur on one side of the head) and are often associated with severe pain, light 
avoidance, sound avoidance, and vomiting (Taylor, 1991). Migraines have been noted to 
occur in distinct phases (Blau, 1980). The phases that have typically been identified are the 
prodrome, aura, headache, resolution, and postdrome. The prodrome phase can occur 
several hours or days before the onset of the headache phase and can serve as a warning of 
6 
an oncoming migraine (Capobianco et al., 1996). Symptoms of the prodrome phase 
include osmorphobia, photophobia , drowsiness, euphoria, irritability, and food cravings. 
The aura phase occurs immediately prior to the migraine attack. The symptoms associated 
with the aura typically last less than an hour and consist of visual disturbances, numbness 
in limbs, and/or language disorders (Capobianco et al.). The headache phase is typically 
characterized by unilateral pulsating head pain that lasts for 4 to 72 hours (Holyroyd & 
French, 1995). Pain diminishes during the resolution phase and during the postdrome 
phase pain is eliminated and all symptoms vanish. The term migraine refers to a headache 
that includes any or all of these phases. It is customary to distinguish between "classic 
migraines ," which include a prodrome or aura phase, and "common migraines," which do 
not. 
Migraine suffers often experience their first episode in childhood or adolescence, 
although onset in the 20s or 3-s is not uncommon. The later the onset of the headache the 
more likely it is to be associated with organic cause ( e.g., cerebrovascular disease or 
tumor; Dalessio, 1994). In a review of the literature on migraine prevalence Stewart, 
Schecter, and Rasmussen (1994) reported that migraine occurs most commonly in 
individuals between the ages of25 and 50. The authors also reported that lifetime 
prevalence rates have been reported in the literature to range from 8-42% of the 
population. Estimates of prevalence vary widely by how migraine headache is defined and 
diagnosed. According to Stewart et al., studies using the clearly defined IHS criteria for 
the diagnosis of migraine typically estimate the lifetime prevalence of migraine to be 
between 24-30% . Migraines are also associated with severe life impairment. A recent 
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review identified that, on average, researchers have found that 50% of individuals with 
migraine headaches miss more than one day of work a year due to headache pain, 50% 
discontinue normal activities, and 30% cancel family and social activities (Stewart et al.). 
Although the economic impact of a migraine headache is difficult to assess, best estimates 
indicate the indirect cost of migraines in the United States to be between $1.4 billion-17.2 
billion a year (de Lissovoy & Lazarus, 1994). While many of the prevalence and impact 
estimates are complicated by migraine classification problems, the above estimates suggest 
that migraine headaches cause serious disruption in the lives of millions of people each 
year. 
There are a variety of current theories that attempt to explain the pathophysiology 
of migraine. Each theory is extensive and highly debated in the research literature. A full 
description of each theory is beyond the scope of this paper. However , several of the most 
influential theories will be briefly discussed . Historically, research on the pathophysiology 
of migraine headaches has largely been driven by the theories generated by Wolff in the 
1940s. Wo I.ff purposed that migraine headaches were caused by increased pressure on 
major cranial arteries. Increased pressure was hypothesized to be the result of prolonged 
dilation of veins and arteries (Taylor, 1991). Dilation was suggested to be triggered by an 
external event. Common events associated with the onset of a migraine have been noted to 
be psychological stress, orgasm, flickering lights, certain foods ( e.g., chocolate and red 
wine), and sound. 
New theories about pathophysiology of migraines have moved beyond WolfPs 
original conception and have begun to explore the biological mechanisms involved in 
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migraine and suggest that the pathophysiology of migraine is much more complicated than 
previously thought. For example, central pain mechanisms have been implicated in the 
production and maintenance of migraines (Raskin, 1988). Specifically, it has been 
hypothesized that abnormalities may occur in the brain stem pain modulation system. 
These abnormalities may cause a rapid depolarization of cerebral neurons and may occur 
during or just prior to the onset of the migraine headache . Others have suggested that 
individuals who experience migraine headaches have an inherited susceptibility to 
headache (Lance, 1993). This susceptibility is thought to be influenced by an interaction 
between exogenous and endogenous factors. Once influenced (by either an internal event 
or external event) the balance between inhibitory and excitatory neurons may be altered , 
which is hypothesized to impact the serotonergic system, vascular pressure , and cranial 
circulation; thereby , producing intense head pain. While most of the new research on the 
mechanisms involved in migraine headache has focused in the biological arena, no 
researchers have ruled out or adequately explained the influence of exogenous factors. 
New theories for migraine headaches are working to identify the specific mechanisms 
involved in the production and maintenance of the migraine. 
In sum, the course of a migraine headache is idiosyncratic and can often be difficult 
to diagnose. Symptom profiles can include intense unilateral head pain, vomiting, and 
photophobia. Many individuals with migraine headaches experience an early onset of pain 
(childhood or adolescence), but, a later onset in not uncommon. Five distinct phases have 
been identified in the course of a migraine (prodrome, aura, headache, resolution, and 
postdrome ). Migraine course is not consistent from individual to individual, thus, any or 
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all of the phases may be present. The pathophysiology of the migraine headache is 
considered to be highly complex and multifaceted. Current theories consider both external 
(triggers) and internal events (biological mechanisms) to be important in the etiology of a 
migraine headache (Capobianco et al., 1996). 
Tension Headaches 
In contrast to migraine headache, tension headaches are characterized by a bilateral 
head pain that is nonpulsing and can last up to 7 days. Head pain in tension headaches is 
usually described as dull, nagging, persistent , tight and constricting (Dalessio, 1994). 
However, the most severe pain in tension headache may occur in the neck and shoulders . 
Tension headaches are not accompanied by nausea, photophobia or phonophobia 
(Holroyd & French , 1995). It has been commonly thought that tension headaches are the 
result oflong-term contraction of cranial and neck muscles (Featherstone , 1985). In 
addition to muscle contraction, some of the same central pain mechanisms that are being 
investigated in migraine headaches have also been implicated in the pathophysiology of 
tension headaches (Raskin, 1988). The prevalence of tension headaches is even more 
difficult to estimate than prevalence of migraine. It has been suggested that the difficulty in 
estimating tension headache syndromes lies in the high levels of self-treatment that occurs 
( over-the-counter medication) and the high degree of overlap that is seen between tension 
headache pain and other clinical syndromes (migraines, back pain, surgical pain; 
Featherstone). Despite these complicating factors, it has been suggested that tension 
headaches (as defined by the IHS criteria) occur in 88% of women and 69% of men 
(Rasmussen, Jensen, & Olesen, 1991). 
Mixed Headaches 
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Mixed headache syndromes are those that consist of discrete periods of both 
tension and migraine headaches. Individuals with mixed headaches may experience both 
migraine and tension headaches within a 1-month period. Reliable estimates of prevalence 
and impact of mixed headache syndromes are not available due to problems with diagnosis 
and research methodology. 
Thus, recurrent headaches are a problem for millions of people each year. The 
migraine is a particularly problematic type of recurrent headache. Migraines result in 
severe head pain, lost work days, and health care costs that exceed a billion dollars a year 
nationally. Migraine headache syndrome is differentiated from tension headache syndrome 
by the type of head pain, the associated symptoms , and the postulated pathophysiology of 
the headache. When migraine headaches and tension headaches both occur in the same 
person, the headache syndrome is classified as mixed type. There is a lack of 
understanding of the etiologic pathways involved in the onset and maintenance of migraine 
headaches and, currently, there is no permanent cure for migraine headaches. However, 
there has been a variety of techniques and pharmacological agents developed that are 
designed to treat migraine headache syndrome. The next section examines these 
treatments. 
Types of Treatment Currently Being Used 
The ambiguity surrounding the pathophysiology of migraine headache syndrome 
has contnbuted to the proliferation of treatment techniques in both medical and 
psychological fields. As one might suspect , medical developments have been largely 
pharmacological in nature; psychological treatments have largely focused on relaxation, 
biofeedback , and cognitive interventions. Pharmacological treatments are numerous and 
varied, thus three major categories and the most popular treatment in each category will 
be briefly reviewed. Then, nonpharmacological treatments will be summarized . The 
purpose of this section is to identify major treatment categories. The results of the 
previous outcome literature will be reviewed later. 
Pharmacological Treatments 
11 
Pharmacological treatments for migraine headaches have evolved significantly over 
the past two decades. Many narrative reviews published in the past few years attempted to 
identify possible medication choices for individuals suffering from migraine headaches 
( e.g., Capobianco et al., 1996; Solomon, 1995). A briefreview of available 
pharmacological agents is provided here (based on Capobianco et al.; Solomon) in order 
to identify the pharmacological modalities used in the treatment of migraine headaches. 
Pharmacological treatments have generally been classified as prophylactic and 
symptomatic treatments (Capobianco et al., 1996). Symptomatic treatments treat the pain 
once the symptoms have begun (Solomon, 1995). Symptomatic treatments are commonly 
used with individuals who have infrequent migraine attacks. Prophylactic treatments are 
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the primary concern ofthis paper, prophylactic therapy is used with patients who have 
regular migraine headaches and works to prevent the onset of the migraine. Capobianco et 
al. report that a prophylactic treatment should only be considered when any of the 
following criteria are met: (a) patients are taking excessive amounts or medication, (b) 
they have regular headaches, ( c) they have attacks that are severe and last more than 48 
hours, (d) the patient is unable to cope with pain and life effects, and/or, (e) attacks occur 
after a prolonged aura. When a client meets one or more of these conditions , several 
classes of medications can be considered. 
There are several major pharmaceutical classes of prophylactic agents. The three 
major classes considered in this project are the beta-adrenergic blockers , calcium channel 
blockers , and anticonvulsants. These three categories are the most commonly suggested 
for use by researchers and physicians (Capobianco et al., 1996) and have the most 
published work on them. Within each class a single agent was chosen for analysis in this 
paper. The agent for analysis was chosen by identifying the one in each class that had the 
most published research (for more details see Methods section). Through this fashion, 
Propranonol (a beta-adrenergic blocker), Flunarizine (calcium channel blocker) , and 
Divalproex Sodium (anticonvulsant) were chosen as the primary targets. Each of the 
agents have brand names, generic names and chemical names (see Appendix A for list of 
agent names). For the purposes of this paper the generic names will be used to avoid 
confusion. A brief review of the properties of each agent follows. 
Propranonol. Propranonol, also known as Propranolol Hydrochloride, has been 
used for migraine prophylaxis for over 30 years. Early reports indicate that practitioners 
13 
observed that patients receiving Propranonol for cardiovascular disorders also displayed a 
decrease in co-existing migraines ( e.g ., Rabkin, Stables, Levin, & Suzman, 1966). These 
observations led to a proliferation ofresearch studies on the use of Propranonol for 
migraine prophylaxis. 
Propranonol is known to have a beta-adrenergic blocking effect that is associated 
with reduced heart rate and blood pressure (Cortelli et al., 1985). It has been suggested 
that this beta-adrenergic blocking interferes with peripheral vasodilator receptors , thereby 
restricting the vasodilation phase of a headache (Cortelli et al.). It has also been sugge sted 
that Propranonol reduces brain wave activity, thus "quieting" the brain response 
(Schellenberg, Milch, Schwarz , & Schoberg, 1994). However, not all beta-adrenergic 
blockers are effective as migraine prophylaxes . Therefore , the mechanisms that account 
for Propranonol ' s effects are still largely unknown (Gerber et al., 1995) . . 
Caroll, Reidy, Savundra , Cleave, and McAish (1990) reported that Propranonol 
has a short half-life ranging from 2-4 hours in its conventional preparation. They go on to 
state that a long acting formula is available which has a half life of 10-20 hours . 
Recommended dosages for migraine prophylaxis range from 40-240 mg. Side effects 
include tiredness , reduced heart rate , reduction of blood pressure, and dizziness (Caroll 
et al.). 
Flunarizine. Flunarizine as a migraine prophylactic has a unique history. Most 
other migraine prophylactic drugs have been extended to migraine patients after an effect 
was noted while treating another condition. Flunarizine does not follow this historical 
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course. Flunarizine is one of the few agents purposed through the scientific method to be 
an effective prophylactic agent for migraine. 
Flunarizine was suggested to be a migraine prophylactic by a group of pharmacists 
(Amery, 1983) after studying the biopathophysiology of migraine. The Amery group 
hypothesized that a period of brain hypoxia was the critical event in migraine genesis. 
Cerebral hypoxia has been associated with the flooding of calcium ions in cerebral arteries 
(Amery). It has been suggested that cerebral arteries are unique in that they require 
external calcium ions to contract ( as opposed to other vasculature that use intracellular 
calcium stores to contract). According to the Amery theory, only a drug that decreased 
the potential for brain hypoxia would be an effective prophylactic agent. Thus , they 
proposed Flunarizine (a unique calcium channel agonist) would be the most ideal agent 
available. Flunarizine is a difluorated piperazine derivative that inhibits the influx of 
calcium ion into vascular smooth muscle cells (Louis , 1981 ). Thus, the use of Flunarizine 
may inhibit the influx of the intercellular calcium ion, thereby reducing the likelihood that 
the cerebral arteries can begin the contraction series seen in migraine (Steardo et al., 
1986). 
Diamond and Schenbaum (1983) suggested that Flunarizine has another property 
that contributes to its success as a migraine prophylactic agent. Research indicates that 
Flunarizine works to block Hl histamine receptors while simultaneously inhibiting 
vasoconstriction and serotonin activity (Diamond & Schenbaum). Histamine and serotonin 
have been shown to be present in the brain in high amounts during migraine activity 
(Steardo et al., 1986). 
Flunarizine has a long half-life ( duration of action is approximately 24 hours), 
which results in a delay in treatment effect (Mendopoulous, Manafi, Logothetis, & 
Bostantzopoulou, 1985). Initial effects are noted between 30 and 90 days (Louis, 1981). 
Recommended doses for migraine prophylaxis range between 5-1 Omg. High doses of 
Flunarizine (more than 30 mg) over long periods of time have been associated with 
reversible Parkinson-like side effects (Schmidt & Oestreich, 1991). More common side 
effects include: daytime sedation (Steardo et al., 1986), weight gain (Amery, 1982), 
depression (Schmidt & Oestreich), dry mouth and skin rash (Martinez-Lage, 1988). 
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Flunarizine is not currently approved by the FDA for use with migraine patients in 
the United States. The reason for this is unknown. The researcher contacted the FDA 
regarding Flunarizine and they responded by stating that it is illegal for them to disclose 
information about an agent under law 21 CFR 314.430. They stated that all information 
belongs to the manufacturer of the agent. Thus, I contacted Janssen-Cilag on four 
occasions to try to get information regarding Flunarizine's drug status in the United 
States. No response was ever received. Janssen-Cilag is a subsidiary of Johnson and 
Johnson. Johnson and Johnson moved many of its production plants to Canada and 
Belgium in the early 1990s. This would have been around the same time the Flunarizine 
would have become a candidate for FDA review. Even without FDA approval, Flunarizine 
is one of the most commonly used and researched prophylactic agent in countries outside 
of the United States. 
Divalproex Sodium. This treatment is composed of one part sodium valproate and 
one part valproic acid (Mathew, 2001). Divalproex Sodium dissociates in the 
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gastrointestinal tract to valproate. Valproate is hypothesized to increase the levels of 
gamma-aminobutyric acid (GABA) in the brain (Mathew). It is thought that the increase in 
GABA levels in the brain serve to reduce the "hyper-excitability" of the brain that is 
thought to be associated with migraine (Shelton & Connelly, 1996). That is, it is believed 
that the brains of individuals with migraines are susceptible to a variety of stressors (both 
physical changes and outside stressors) . This is believed to cause the brain to be 
hyperexcitable and cause a vasoconstriction reaction that will start a migraine. 
Divalproex Sodium is also thought to have additional properties that aide in 
migraine prophylaxis . It is suggested that Divalproex Sodium may inhibit the release of 
prolactin (Jensen, Brink, & Olesen, 1994). Prolactin is thought to be released in high levels 
during an ischemia (Shelton & Connelly, 1996). Thus , it is thought that Divalproex 
Sodium may offer some protection against migraine during the aural phase. 
Divalproex Sodium has been used for epilepsy, infantile spasm, photosensitive 
epilepsy, and migraine (Silberstein & Wilmore, 1966). The FDA has approved Divalproex 
sodium for use as a migraine prophylaxis. The plasma half life ofDivalproex Sodium is 8-
17 hours (Silberstien & Wilmore). Recommended doses for migraine prophylaxis are 400-
2500 mg a day and migraine reduction is likely to be seen in 30 days (Landy & McGinnis, 
1999). Most of the agent is metabolized in the liver, which can result in liver damage if 
appropriate levels are exceeded (Shelton & Connelly, 1996). Documented side effects can 
include tremor, weight gain, alopecia (Thomas, 1989), gastrointestinal disorders, and 
gastroesophageal reflux disease (GERD; Landy & McGinnis); 
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Nonpharmacological Treatments 
A variety of nonphannacological treatments have been developed to treat migraine 
headache syndrome . These treatments are based on the theory that controllable responses 
like stress , tension, heart rate, blood pressure, and negative cognitions contribute to the 
development, maintenance, and interpretation of the recurrent migraine. The most 
commonly researched nonphannacological treatments are briefly reviewed here. It is noted 
that each treatment described is rooted in a theoretical orientation, has extensive treatment 
procedures, and has many treatment variations . However, a full discussion of all of these 
issues is beyond the scope of this paper. 
Biofeedback treatments . In a recent nonquantitative review of supported 
psychological treatments for migraines , Holroyd and French (1995) report that thermal 
biofeedback plus relaxation training and EMG biofeedback plus relaxation training are two 
of the most widely used nonpharmacological treatments for migraine headaches. 
Biofeedback is a method of achieving control over bodily processes that are usually 
outside of the client's awareness. Biofeedback targets a function (hand warming in thermal 
feedback and muscle tension in EMG biofeedback) and provides continuous feedback 
(typically visual and/or auditory) regarding the target function to the client (Taylor, 1991). 
With continuous feedback, typically provided via a computer, and through trial and error, 
clients learn to gain control over their target functions. After successful training clients are 
theoretically able to control their target function without the use of the mechanical 
feedback (Blanchard, 1994). 
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Relaxation treatments. Relaxation training is also used to treat clients who suffer 
from migraine headaches. Relaxation training guides the client to move toward a less 
physiologically aroused state (Taylor, 1991 ). Procedures for relaxation training may use 
any combination of deep breathing techniques , muscle relaxation, and imagery (Malone & 
Strube, 1988). Treatments typically involve five to eight sessions and include some form 
of daily home practices. Clients may be given workbooks or audiotapes to aide in their 
practice at home. In some cases , relaxation techniques have been used as the sole 
treatment or in combination with biofeedback. 
Cognitive treatments. Another commonly reported treatment for migraine 
headache sufferers is cognitive or cognitive-behavioral therapy. Cognitive treatments are 
aimed at helping clients alter their perception of pain. In cognitive treatments , clients meet 
with a therapist and learn to monitor the thoughts , feelings, and behaviors that enhance 
their sensation of pain (Holroyd & French , 1995) . Clients then learn to alter their behavior 
and thinking to patterns that are associated with less pain. Common protocols for migraine 
prophylaxis that use cognitive training use components of rational emotive therapy and 
coping skills training. 
Summary 
In summation, none of the above described treatments are considered to be a 
"cure" for migraine headaches. Rather, both the pharmacological and nonpharmacological 
treatments seek to reduce the duration , intensity, and frequency of pain in clients 
(Solomon, 1995). Between the pharmacological and nonpharmacological categories there 
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are over 30 different treatment options. Treatment choices become even more confusing 
when turning to research for guidance. A simple perusal ofMEDLINE and PSYCHINFO 
databases reveals that each treatment option has many (from 2 to 12) primary studies 
touting its "effectiveness." It is apparent in the above description of available treatments 
that the abundance of choices can be overwhehning for professionals and consumers. The 
data regarding the effectiveness of all the treatments for migraine headaches needs to be 
quantitatively analyzed so that treatments can be compared to one another. A meta-
analysis is a good vehicle for this kind of analysis of multiple primary studies (Carroll, 
1996). Thus, a comprehensive meta-analysis was undertaken to evaluate the effectiveness 
rates of six empirically supported pharmacological and nonpharmacological treatments for 
migraine headache syndrome. 
Suggested Evidence for Evaluating the Effects 
of Treatments 
It is important to have a common understanding of the meaning of a "potent 
treatment" before attempting to compare the effects of various treatments. Guidelines 
have recently been proposed for defining efficacious and effective treatments. Chambless 
and Hollon (1998) detailed minimum research requirements for an efficacious treatment. 
First, they stated: 
Treatment efficacy must be demonstrated in controlled research in 
which it is reasonable to conclude that benefits observed are due to the 
effects of the treatment and not to chance or confounding factors such 
as passage of time, the effects of psychological assessment or the 
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presence of different types of clients in the various treatment conditions . 
(p. 7) 
The authors also recommend that at least two controlled studies, conducted by 
independent researchers, need to be conducted for a specified condition. This is a 
particularly salient issue for many of the pharmacological treatments of migraine 
headaches. Many medications are recommended for use with migraine headache sufferers, 
yet lack controlled studies to support their use for this specific purpose. 
Chambless and Hollon (1998) described some designs that should be given more 
weight when attempting to evaluate the efficacy of a treatment. Randomized trials are 
considered to be the "gold standard" for treatment evaluation and constitute the best 
evidence. In addition, treatment evaluation should be considered hierarchal in nature. 
Results that come from treatment studies with no comparison groups should be held more 
tentatively than results from studies comparing treatment to a control, placebo, or no 
treatment group. Better yet are results from studies that compare effects of a new 
treatment to the effects of another established treatment. According to Chambless and 
Hollon, this is the premier type of efficacy research. Comparison studies that examine the 
treatment effects of two or more treatments can result in explicit information regarding 
relative benefits of the two treatments. Unfortunately, in the area of migraine headache 
there are only a few primary studies that compare the treatments to each other. Those that 
do compare treatments typically compare them within the same category (e.g., EMG 
biofeedback to thermal biofeedback or Propranonol with Flunarizine ). Primary studies that 
compare treatments between groups are very rare. It has been suggested that this may 
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occur because medical and nonrnedical professionals become so exclusively focused on 
their treatment modalities that research collaboration seldom occurs (Holroyd & Penzien, 
1990). However, the lack of primary research comparing the numerous treatment 
modalities available for treating migraine headaches does not abate the need for 
professionals and clients to be able to evaluate the relative effects of the treatments. 
One possible solution to this problem is a large-scale evaluation project. Such a 
project could compare each available treatment option for migraine headaches, tension 
headaches , and mixed headaches in a controlled evaluation. However , the number of 
needed subjects to do a primary research study comparing the success or improvement 
rates of treatments for migraine headaches would be enormous. Chambless and Hollon 
(1998) recommended that a minimum of 50 subjects per condition should be used in 
efficacious research. If this guideline were adhered to , a research study examining 
outcome of the most common treatments for migraine headaches would require 
approximately 1700 subjects. Even more subjects would be needed if each treatment 
group were to be matched with a control group. The project would require collaboration 
between many groups and professionals and would be costly to conduct. However, the 
information provided in such a study would be invaluable. Even if this type of large scale 
study were conducted, replication would be needed before confidence could be gained in 
the results. 
In the absence of such large scale projects another alternative is available. The use 
of meta-analytic techniques as suggested by Glass (1976) allows for the quantitative 
analysis of a large number of primary analysis results for the purpose of integrating and 
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comparing these results. A meta-analytic review comparing all methods of treatments for 
migraine headaches would provide a way for previously obtained results in each individual 
area to be compared and evaluated. 
Previous Reviews 
In preparing to conduct a meta-analytic review, it is appropriate to evaluate 
previously conducted reviews on related topics (Glass, 1976). This allows the new meta-
analytic review to benefit from previously obtained data and avoid pitfalls that others may 
have encountered. The area of treatment efficacy research for migraine headaches is 
marked by several well-conducted quantitative reviews and many insightful narrative 
reviews. Reviews were identified by using combinations of the key words "review," 
"effective," ' 'treatment ," "migraine," "pain," "outcome," and "headaches" in both the 
MEDLINE and PSYCHINFO databases (1970 to 7/2003) . This search strategy identified 
102 reviews. Of these, 19 were in a foreign language and 36 presented only information of 
the pathophysiology or diagnosis of headaches. In addition, a substantial number (N = 32) 
of pharmacological reviews were eliminated because they did not meet selection criteria. 
For example, many reviews in pharmacological literature present only an author's personal 
experience with, or opinion of, a treatment for migraine headaches. These reviews do not 
evaluate controlled studies and provide little information about the effectiveness of the 
treatments. Thus, the reviews presented here (N= 12) met the following criteria: (a) the 
review provided information regarding the effectiveness of a recurrent headache 
treatment(s) in either narrative or quantitative form, (b) if the review was narrative then it 
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must review empirically conducted research, and ( c) the review was written or translated 
into English. 
The reviews presented here are evaluated by quality of research design based on 
six criteria: (a) selecting and delimiting the topic, (b) review of previous reviews in 
relevant areas, ( c) selecting an appropriate sample of studies, ( d) data collection 
procedures, (e) analyzing results, and (t) interpreting and reporting results. Based on these 
criteria, each review was given an excellent, good, or poor rating. Recommendations 
based on the literature will be followed by a brief critique of the available reviews in each 
area. 
This paper's examination of previous reviews is broken up into five separate 
sections. The first examines those reviews which attempt to compare effectiveness rates of 
treatment(s) from the pharmacological category with treatment(s) from a 
nonpharmacological category. Again, according to Chambless and Hollon (1998), this 
type of comparative information is considered to be the "best evidence," thus, these 
reviews are considered first and in some detail. Then, reviews that considered just 
pharmacological treatments for headaches are examined, followed by reviews that 
considered only nonpharmacological treatments. Then, other relevant reviews that 
provided valuable information about potential correlating variables will be briefly 
examined. Finally, a recent work that critiques meta-analyses in general will be discussed. 
A brief summary of major findings and considerations of each existing review can be found 
in Appendix B. 
Reviews Comparing Pharmacological and 
Nonpharmacological Treatments 
There are only two existing reviews that integrate pharmacological and 
nonpharmacological treatments for recurrent headaches in adults. One of these reviews 
focused solely on treatments for migraine headaches, the other focuses on tension 
headaches. The first of these reviews compared the effectiveness of a biofeedback/ 
relaxation combination treatment to medical administrations of Propranonol in adult 
migraines. The second review focuses on both pharmacological and nonpharmacological 
treatments for tension headaches in adults. These meta-analytic reviews are of varying 
quality, but all provide valuable insight into treatment outcome in recurrent headaches. 
Holroyd and Penzien 
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The first meta-analytic review is an excellent evaluation of the treatments for adult 
migraine headaches. This review compared the treatment effects of Propranonol and 
relaxation/biofeedback training. Holroyd and Penzien (1990) used meta-analytic 
procedures to examine results of primary research studies conducted up to 1989 in 
migraine suffers (although some mixed headache suffers were included). Four conditions 
were compared in this review: Propranonol, biofeedback/relaxation, placebo, and no 
treatment conditions. 
Change was variably calculated in the Holroyd and Penzien (1990) review. First, if 
the primary research articles reported a headache index score, this was used as the change 
index (the headache index is a composite score that weights and combines intensity and 
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duration of headaches). However, an undetermined number of studies did not report 
enough data to calculate the headache index score; therefore, for some studies the authors 
calculated a "composite headache index score." This score was calculated from an average 
ofreported scores (any or all of frequency, duration, and intensity change scores). Authors 
reported a significant correlation (r = 0.86) between the two methods of calculating 
change (headache index and their composite headache index score). 
Holroyd and Penzien (1990) coded for method of estimating change improvement 
scores. Some of their primary studies used daily recording journals , where others had 
practitioners make end-of-treatment gain estimates. The authors found that results differed 
by approximately 20% if daily headache measures were used to calculate change. That is, 
the reported improvement in headache activity was 20% lower in studies that had 
participants rate their headache daily rather than having a therapist or physician rate the 
change. This difference was significant (p < 0.001). Calculations examining only the data 
from the studies employing the daily recording of headache activity revealed 43.3 % mean 
improvement in headache in both the Propranonol and the relaxation/biofeedback 
conditions. Both Propranonol and biofeedback/relaxation showed significantly (p < 0.001) 
higher treatment effects than the placebo and untreated conditions. 
These authors based their results on two different types of change scores. In some 
studies the change score (the headache index) was taken directly from the primary report . 
In other cases the authors averaged across three variables ( duration, frequency, and 
intensity). The headache index does not account for frequency thus the two methods of 
computation may have led to dramatically different results. In addition, this review 
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examined only one type of prophylactic treatment, Propranonol, and excluded the others. 
Propranonol is the most frequently prescribed prophylactic pharmacological treatment, 
however, this does not indicate that Propranonol is the most efficacious treatment or the 
only one worthy of study. Also, Holroyd and Penzien examined only studies through 
1989. Over 40 new studies have been published on treatments for migraines in the last 9 
years. These additional studies could render some of the Holroyd and Penzien's 
conclusions outdated. Finally, it is noted that the authors make a particularly important 
recommendation for future research. They note that while effectiveness rates are 
compared at the end of treatments it is unclear what long term effects, if any, these 
treatments have. 
Technical Review Conducted by Duke University 
and the Center for Clinical Health and 
Policy Research 
The second review is a two-part review developed in part for the Agency for 
Health Care Policy and Research. This study has not been published (likely due to length 
and complexity) outside of the NTIS Website. The review was posted (at NTIS) after the 
proposal date of the current project and it mirrors many of the current author's intentions. 
The first part of the part of this review (authored by Duke University and The Center for 
Clinical Health Policy and Research, 1999a) synthesizes the data for behavioral and 
physical treatments for migraine. The second part (Duke University and The Center for 
Clinical Health Policy and Research, 1999b) synthesizes the data for prophylactic 
pharmacological agents for migraine. This methodologically sophisticated review is 
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excellent in most aspects. The review only included randomized controlled trials of 
pharmacological , psychological , behavioral and physical (e.g. , acupuncture) treatments. A 
comprehensive group of findings are presented that include more than the six treatments 
evaluated by the current meta-analyses. Findings from this excellent quantitative review 
indicated that most pharmacological and nonpharrnacological treatments had functionally 
equivalent effect sizes (all of which were in the moderate range). A similar pattern and 
magnitude of findings was reported for nonpharmacological treatments. 
Standardized mean difference effect sizes for nonpharrnacological treatments 
ranged from .08-1.61. The nonpharrnacological treatments and summary weighted mean 
effect sizes are as follows: relaxation (es= .55), thermal biofeedback (es= .38), thermal 
biofeedback plus relaxation (es = .40), E.G. biofeedback (es = .77), cognitive behavioral 
therapy (es = .54), and thermal biofeedback plus cognitive therapy (es - .37). The 
pharmacological meta-analysis examined 52 treatments that included hormonal treatments 
for menstrual migraine. They report that the top seven agents with their effect sizes are 
naproxen sodium (es= .62), Flunarizine (es = .52), Propranolol (es= .55), amitriptyline 
(es= .62), Timolol (es= .69), pizotifen (es = .91), Divalproex Sodium (es= .93). The 
other pharmacological agents examined in this study were reported to have variable results 
with low effect sizes. 
However, this meta-analysis does not compare the findings between the two 
groups. Instead they report their findings in two separate reports in two separate formats. 
Of additional interest was the authors' choice in this review to use varied statistical 
procedures for pharmacological studies and nonpharrnacological studies. Standardized 
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mean difference scores and odds ratios are calculated for pharmacological studies, non 
pharmacological studies include standardized mean differences and percent improvement 
measures. This is curious given the emphasis on consistency of evaluation methods across 
domains. The percent improvement scores were used in the Duke study as a cross check 
for standardized mean difference scores. The authors reported that the percent 
improvement scores in some cases underestimated treatment effects. In addition, percent 
improvement scores have been criticized because this procedure averaged unstandardized 
data and can be misleading. 
Summary of Reviews That Compare Pharmacological 
and Nonpharmacological Treatments 
A total of two reviews exist that evaluate pharmacological and 
nonpharmacological treatments for recurrent headaches. An evaluation of the these 
reviews indicates that: (a) Propanonol, relaxation training , biofeedback , and cognitive 
therapies all have been reported to produce similar treatment outcomes and improvements 
in migraine sufferers (both adults and children); (b) percent improvement scores may 
underestimate treatment effect; and ( c) type of outcome measure highly influences the 
results of the study. 
Cumulatively, the reviews identify several pitfalls for future researchers. First, 
change scores should be calculated for frequency, intensity, and duration if headache 
scores are not available. If standard deviations are presented in primary literature, 
standardized effect sizes should be calculated. Next, it may be wise to use all available 
studies and code for quality rather than eliminate studies due to methodological flaws. 
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Finally, when examining both pharmacological and nonpharrnacological studies 
researchers should report specific treatment effects, in addition to categorical effects (i.e., 
pharmacological or nonpharrnacological). 
Pharmacological Reviews 
This section examines those reviews that focus on pharmacological treatments. 
Two quantitative reviews on migraine headaches exist in this area. (Holroyd, Penzien, & 
Cordingley, 1991; Onghena & Van Houdenhove , 1992). Other narrative reviews are 
available (e.g., Capobianco et al., 1996; Solomon, 1995), however, the reviews are 
primarily informational in nature and focus on side effects of the medications and 
contraindications. This section will focus only on those reviews that are quantitative in 
nature. 
Holroyd, Penzien, and Cordingley 
The Holroyd et al. (1991) review examines existing literature on the effectiveness 
of Propranonol as a prophylactic treatment for recurrent migraines. This review 
synthesized data from 53 studies, which resulted in a total of 73 groups (Propranonol and 
placebo). The Holroyd et al. review calculated two different types of change scores. The 
first was pre-post treatment gains, the second subtracted gains of the placebo groups from 
the gains of the treatment (Propranonol) groups. Change scores were analyzed separately 
and results varied significantly by method of calculation. That is, change scores were 
lower when placebo groups were used in the calculation instead of pretreatment scores. 
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The Holroyd et al. review concludes, that on, average prophylactic use of Propranonol 
results in a 44% reduction in migraine activity when the most conservative outcome 
measures are used (patient daily diaries) and when change is compared to placebo groups. 
Estimates are higher when less conservative measures are used ( clinician ratings of pre-
and posttreatment scores). 
This review is considered to be excellent because it has clear selection criteria and 
identifies correlates of treatment outcome (age, gender, mortality, mortality due to side-
e:ffects, dose of active agent , chronicity of headache, and quality of study). While 
providing excellent information about the use of Propranonol , the net result is information 
that is difficult to interpret. This is because Propranonol is compared only to placebo 
groups and not other treatments. Thus, it is difficult to identify whether Propranonol is 
better, equal to , or worse than other prophylactic treatments. The authors of this review 
report that Propranonol has equal effectiveness rates to other phannacological 
prophylactic treatments, but no data are provided to support this position. 
Onghena and Van Houdenhove 
Onghena and Van Houdenhove (1992) conducted a good meta-analytic review of 
antidepressant-induced analgesia in chronic pain patients. Thirty-nine placebo controlled 
studies were examined; 10 were conducted with migraine, tension headache, or mixed 
headache subjects. This review provides an adequate description of selection procedures, 
the problems with primary research validity, quality of study, compliance, and types of 
medication used. Conclusions indicate that patients with migraines, tension headaches, and 
mixed headaches showed statistically significant improvements in their headache activity 
when using an antidepressant medication. In addition, larger effect sizes were noted for 
recurrent headache patients than any other pain category . 
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Yet, the findings in the Onghena and Van Houdenhove (1992) review are difficult 
to interpret because they do not compare the analgesic effects of antidepressants to 
analgesic effects of any other pharmaceutical agent. The results of this meta-analysis are 
important , but difficult to integrate with other analgesic findings. However , this review is 
one of the few that quantitatively evaluate pharmacological treatments , thus providing 
important design information. In this study it was recorded whether other drugs were 
allowed to be taken during the study, the activating profile of the drug (psychomotor 
activation, nonactivating/nonsedating , and sedating) , in-patient status, mean age, duration 
of pain, side effect profiles of the drugs, numbers of subjects dropping out due to side 
effects, and patient profiles indicating drug selection. 
The last point is of particular interest. Many of the pharmacological interventions 
have a highly selective process to determine if subjects can safely take the medication. 
Selection processes may include the consideration of pre-existing medical conditions, age, 
previous response to medications, current medications taken, and side effect profiles of the 
pharmacological agent (Solomon, 1995). This selection process may introduce a selection 
bias that is not comparably matched in the nonpharmacological research that may cause 
problems in the comparison of the two interventions. To best attempt to compare the 
pharmacological and nonpharmacological treatments the above information should be 
gathered on all primary studies (pharmacological and nonpharmacological). 
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Summary of Pharmacological Reviews 
Both of these reviews offer insight into procedures that are helpful when reviewing 
pharmacological literature. For example, Holroyd et al. (1991) suggested that change 
scores should be calculated in two forms and then results should be analyzed separately. 
The Onghena and Van Houdenhove (1992) review suggests that reviews of 
pharmacological research should examine several variables. These include; identification of 
other medications taken (analgesic and others), inpatient status, age, and duration of pain. 
In addition, both reviews (Holroyd et al.; Onghena & Van Houdenhove) indicated that 
overall mortality rates versus mortality rates due to medication side effects should be 
coded separately. 
Nonpharmacological Reviews 
One review that examines adult migraine headache treatment is available in the 
nonpharmacological area. Compas, Haaga, Keefe, Leitenberg, and Williams (1998) 
examine the outcome of biofeedback, relaxation, and cognitive treatments. Unlike the 
pharmacological reviews, this review makes comparisons between treatments that provide 
valuable insight into the effectiveness of treatments in relation to one another. 
In narrative form, Compas et al. ( 1998) reviewed all empirically supported 
nonpharmacological treatments for smoking, cancer, chronic pain, and bulimia nervosa. A 
subsection is included on migraine headaches that reviews thermal and E.G. biofeedback, 
relaxation, cognitive therapy, and cognitive behavioral therapy. Most of the information in 
this narrative review is based on previously mentioned quantitative reviews. The authors 
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report that many of the previously conducted meta-analyses have been supported by more 
recent work. Nevertheless, there was no attempt to quantitatively review the more recent 
work. Furthermore, Compas et al. evaluated the effectiveness of cognitive and cognitive-
behavioral treatments (both of which are treatments that have not been adequately 
quantitatively reviewed) and concluded that cognitive treatments are not effective in 
reducing migraine headache activity. 
The Compas et al. ( 1998) review was written simultaneously with the Chambless 
and Hollon (1998) recommendations for evaluating empirically supported treatments. As 
such, Compas et al. clearly identify studies that are randomized , provide correlational 
evidence, and compare to other treatments . The list of studies generated by Compas et. al, 
while not inclusive, would be essential to include in a future meta-analysis. 
Other Relevant Reviews 
Four other reviews will be briefly discussed. They are not specifically focused on 
the treatment of migraine headaches, but they provide valuable information about potential 
correlates and coding procedures. Because these reviews are less directly related to the 
current topic , they will only be discussed briefly. 
Flor, Fydrich, and Turk (1992) 
This is an excellent meta-analytic review which investigated the efficacy of 
multidisciplinary pain clinics. The authors investigated age, marital status, education level, 
socioeconomic status (SES), employment status, compensation, litigation, and medication 
use. However, none of the above were found to correlate significantly with study 
outcome. Though the Flor et al. study focused primarily on the treatment of back pain 
patients in pain clinics, the noted correlates may be important when evaluating migraine 
headaches. 
Lander 
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Lander ( 1990) also provided a narrative review on pain management. While not 
specifically addressing migraine headaches , Lander highlights the importance of client and 
researcher variables in evaluating pain management techniques . Variables considered to be 
important are: (a) practitioner inference about treatment gains "polluting " the outcome 
measures , (b) potential differences in convenient , solicited , clinical, and nonclinical 
populations , (c) gender , SES, and age as mediating variables, and (d) duration of pain. 
Holroyd and Penzien 
In 1986, Holroyd and Penzien conducted a meta-analysis that examined both 
client variables and treatment variables that may impact the treatment of tension headache. 
This review focused solely on tension headaches and nonpharmacological interventions. 
Type of treatment, length of treatment, training of therapist, and attention to transfer 
training did not significantly correlate with treatment outcome. However, sample 
characteristics were found to significantly correlate with the reported reduction in 
headache activity. Most dramatically, treatment outcome varied by age, gender, and 
solicited, rather than referred clients. Primary studies with younger mean ages, more 
females, and solicited samples all reported stronger treatment effects. 
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Malone and Strube 
In contrast to Holroyd and Penzein (1985), Malone and Strube (1988) found that 
sample characteristics were not correlated with outcome of psychological treatments. 
Malone and Strube conducted a meta-analysis of effective nonpharmacological treatments. 
However, Malone and Strube collapsed across types of pain treatment ( e.g., headache, 
backache , cancer) . In addition, Malone and Strube calculated change scores for primary 
studies that did not report pretesting by estimating from studies that did have similar 
pretests. This procedure is based on questionable assumptions and is likely to mask true 
differences. Given the procedural errors, the Malone and Strube meta-analysis was given a 
poor quality rating and thus, the evidence presented in the Malone and Strube review is 
not convincing. 
Reviews of Meta-Analytic Reviews 
Finally, one excellent quantitative review has been conducted using previous meta-
analytic reviews that have examined analgesic interventions (Jadad & McQuay, 1996). The 
article is primarily focused on identifying weaknesses in the current reviews and making 
recommendations for reducing bias and improving quality. Jadad and McQuay report that 
a simple MED LINE search missed nearly 50% of relevant articles making many of the 
medically based meta-analyses incomplete. In addition, the importance of completely 
identifying the methods used to locate primary studies and describing criteria for assessing 
validity of primary studies was highlighted. While these recommendations are standard for 
conducting a meta-analysis, Jadad and McQuay report that 26% of meta-analyses 
reviewed did not identify the selection methods, and 21 % did not identify design 
characteristics of their sample. 
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Other important issues in meta-analysis research identified by Jadad and McQuay 
(1996) are the quality and validity of the primary study. As mentioned above, many 
authors have reported that quality of primary study is an important outcome variable ( e.g., 
Blanchard, Andrasik, Ahles, Teders , & O'Keefe , 1980; Bogaards & ter Juile, 1994; 
Holroyd & Penzien, 1985; Onghena & Van Houdenhove, 1992). Authors of meta-
analyses often evaluate the quality and validity of primary studies because it has been 
hypothesized that primary studies of poor design with threats to validity may produce 
higher effect sizes than studies of good quality (Slavin, 1984). Therefore , the conclusions 
of a meta-analysis may be overestimates if the author does not account for the quality of 
the primary studies it includes. Jadad and McQuay reported that while many authors 
report that they evaluated quality of study, 60% of meta-analyses did not describe 
methods of assessing primary study validity and quality. Jadad and McQuay reported that 
a good meta-analysis includes a systematic and objective method of assessing quality and 
validity of primary studies that is specifically described in the text. 
In summation, there are 12 applicable reviews in this area. Only a few of these 
reviews have compared treatments to each other. Two compared treatments across 
categories (nonpharmacological and pharmacological), but only one of these reviews 
(Holroyd & Penzien, 1990) focused directly on migraine. The Holroyd and Penzien review 
did not comprehensively examine multiple pharmacological and nonpharmacological 
agents. A review of multiple pharmacological and nonpharmacological treatments is 
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available for tension-type headaches (Bogaards & ter Kuile, 1994), but none exist in the 
migraine literature. The remaining reviews studied the outcome of treatments within a 
single category (i.e., relaxation and biofeedback in the nonpharmacological category). The 
pharmacological reviews did not compare treatments at all, instead , they compared 
treatments only to placebo or control groups. The net result of these reviews is a wealth of 
information that is almost as difficult to interpret and use as the individual primary studies. 
Summary 
Migraine headaches are a disabling problem for millions of Americans . There are 
over 30 treatments available for migraine headaches. Much of the primary research in the 
area of migraine headaches is focused on identifying the effectiveness rates of these 
treatments in comparison to control or placebo groups. This procedure does not allow for 
the comparison between treatments. Only seven primary studies have conducted research 
that compares a pharmacological and nonpharmacological intervention. As a result, there 
is a wealth of data on individual treatments that is difficult to compare to one another and 
use (Chambless & Hollon, 1998). A synthesis is needed to make the data more 
manageable. There have been a variety of systematic reviews conducted in this area, 
however, their focus is too narrow and some are now outdated. Therefore, a more 
comprehensive meta-analysis that includes an evaluation of both pharmacological and 
nonpharmacological treatments on migraine headaches needs to be conducted. 
38 
CHAPTER III 
PURPOSE OF STUDY AND RESEARCH QUESTIONS 
The purpose of this study was to integrate data available on pharmacological and 
nonpharmacological treatments for migraine and mixed headaches. Mixed headaches were 
being included because of the high overlap between the two syndromes. This study is a 
meta-analysis and, thus , will quantitatively compare effectiveness rates of many different 
treatments . 
1. How do the effectiveness rates of treatments compare to each other and 
between groups (pharmacological and nonpharmacological)? 
· 2. What sample characteristics are significantly correlated with outcomes? Do 
these characteristics vary by treatment category? 
3. Do outcomes vary if broken into two levels of empirical evidence (placebo 
control group comparison, and multiple treatment comparison) as suggested by Chambless 
and Hollon (1988)? 
4. What information is available regarding short and long term effectiveness rates 
for pharmacological and nonpharmacological studies? 
CHAPTER IV 
METHODS 
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The methods used in this meta-analysis are described below. First, procedures for 
selecting the treatments and primary articles to be evaluated are discussed. Then, a 
description of the sample with a list of articles included in the meta-analysis is provided. 
Data collection and quality rating methods are discussed next. Finally, methods and 
rationales for analysis are presented. 
Selection of Sample 
The selection of studies to be included in the current meta-analysis followed a 
multistep procedure. First, popular classes of treatment were identified, then the most 
frequently researched treatments within the class were identified. Once identified, all 
outcome studies regarding the treatments were gathered. A search strategy was developed 
to ensure comprehensiveness. Once primary articles were obtained, inclusion and 
exclusion rules were applied. Each of these steps are described in turn below. 
The current meta-analysis identified six different treatments for migraine 
prophylaxis to compare. Treatments to be evaluated were selected by conducting a 
preliminary literature search of available classes of treatments. In the pharmacological 
treatment area a preliminary literature search identified three major pharmacologic classes 
that are currently being researched for use as prophylactic agents: beta-blockers, calcium 
agonists, and anticonvulsants. Once these classes of medications were identified, a more 
40 
comprehensive abstract search identified which pharmacological agent had the greatest 
number of controlled published research outcome studies. This process identified the top 
three agents in each category; Propranonol , Flunarizine, and Divalproex Sodium. This 
process was duplicated for nonpharmacological prophylactic treatments for migraine. The 
preliminary literature search in the area of nonpharmacological treatments identified 
thermal biofeedback, relaxation therapies, and mixed therapy treatments as the most 
researched areas. 
Once the treatments for inclusion in the meta-analysis had been identified, a more 
comprehensive literature search began. A search for published , peer-reviewed literature on 
the effectiveness of each treatment was conducted. Literature published between 1970 to 
July, 2003 was included in the search. This search included searches ofMEDLINE, 
PSYCHINFO , ERJC, and the Current Contents databases. Key words used in database 
searches included combinations of the following: the treatment names, controlled , random , 
effectiveness , prophylaxis, migraine, headache, vascular headache , treatment , and 
outcome. In addition, reference sections of reviews on these treatments were checked and 
cross-referenced to ensure comprehensiveness. Finally, the last year (2002-2003) of Pain, 
Headache, Journal of Consulting and Clinical Psychology, Journal of the American 
Medical Association, & Cephalalgia were reviewed for newly published articles that may 
have not been accounted for in the computer-based search. 
After articles had been identified in the above-mentioned treatment categories, a 
set of inclusionary and exclusionary rules were applied to each article. Inclusion rules 
included (a) three studies examining a single treatment for migraine headaches must exist 
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for a treatment to be considered in the meta-analysis, (b) studies had to have at least five 
subjects in each condition to be considered in the meta-analysis, ( c) study evaluated a 
pharmacological or nonpharmacological treatment for migraine or mixed headache, and 
( d) study must provide enough numerical detail to calculate at least one change score per 
condition. Studies were excluded from the analysis if (a) the study did not compare the 
treatment to a placebo, control group or comparison treatment,(b) the study was 
conducted with animals, ( c) the study only examined children under the age of 18, ( d) the 
study was published in a foreign language, ( e) the study reported on the same data that 
had already been reported elsewhere, (f) the study employed a single-subject research 
design, and (g) the study was an analogue study. 
Description of Sample 
Approximately 400 articles were obtained and cataloged via a database system. 
This number includes approximately 200 articles that were eliminated because they 
evaluated the wrong treatments, were reviews, did not provide original data, provided 
practitioner guidelines only, or had a focus other than treatment outcome evaluation. The 
selection criteria were then applied to the 191 remaining articles. Careful documentation 
was kept on each article that was excluded. This process resulted in examination of 57 
articles in the Propranonol category and the retention of 30 articles, 52 articles in the 
Flunarizine category and the retention of 17 articles, and 18 articles in the Divalproic 
Sodium category and the retention of seven articles. In the nonpharmacological area many 
of the primary studies were multi-arm studies that provided information on more than one 
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treatment being included in the analysis. Thus, the sample is best described as a sample of 
64 articles from which 15 studies were used to calculate 18 effect sizes in the thermal 
biofeedback category. Four articles were retained in the relaxation therapy category. Nine 
articles were used in the mixed therapy category (five EMG biofeedback articles and four 
thermal biofeedback plus relaxation plus cognitive therapy). This resulted in 82 studies 
being retained overall and included in the study, and 109 studies being excluded. 
It should be noted that a large number of nonpharmacological studies were 
excluded due to insufficient reporting of data in the write up. Many studies in the 
nonpharmacological area were well-designed controlled studies. Interestingly, a number of 
authors attempted to use forms of relaxation or meditation as a control condition. 
However , these "control groups " have been identified as active treatments within the 
primary study and in subsequent research. Thus, the studies using relaxation controls are 
actually comparison studies between two treatments . Because of their conceptual premise , 
commonly authors had developed a priori hypotheses only about the difference between 
the so-called control group and the treatment group. Therefore, many of these studies 
only reported a nonsigni:ficant finding for an independent t test. Nonsigni:ficant results can 
be used to calculate an effect size if exact t and or p values are given. However , the 
common practice for reporting non-significant results is with lower bounds ( p > .05) or 
without numerical data (t = N.S.) Reporting results in this manner precludes the 
calculation of effect sizes, and thus violates inclusionary rule ( d). This is an unfortunate 
loss of data and results in a relatively small number of articles being available for 
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evaluation in the nonpharmacological treatment area. Those included are listed below by 
categories in Tables 1 to 4. Lists of excluded can be found in Appendix C. 
Data Collection 
Once a study was identified as meeting all of the criteria for being included in the 
current meta-analysis, it was coded for a variety of information (see Appendix D for 
copy). Variables coded included sample used in the primary study, sample size, year the 
study was published, percent female, type of control group used, randomized assignment, 
mortality rate, and design of study (parallel or cross-over). In addition, quality of study 
was coded in two separate ways. The first quality of study measure used is a research-
based instrument developed by Jadad et al. (1996). This instrument codes randomization, 
double-blind features, and descriptions of dropouts . It been shown to have high inter-rater 
reliability because of its objective descriptions of criteria (Jadad et al.). Scores for articles 
being rated range from zero to five, with higher scores indicating a better quality report. 
The second measure was created to examine quality issues specifically related to the 
headache literature. Items include presence of wash-out or run in periods, types of 
recording used, comparison groups used, type of setting, and control of medications/ 
treatments. This measure has scores ranging from one to three, with higher scores 
indicating a better quality of report (see Appendix E for copy). This measure was checked 
for inter-rater reliability by having a second PhD level psychologist code a randomly 
chosen set of articles ( approximately 15% of the total). The reliability coefficient for the 
Table 1 
Primary Articles That Were Included in the Meta-Analysis for Propranolol 
Authors 
Ahuja & Verma (1985) 
Albers, Simon, Hamik, & Peroutka (1989) 
Andersson & Petersen ( 1981) 
Borgesen, Nielsen, & Moller (1974) 
Daho If ( 1987) 
Diamond & Medina ( 197 6) 
Diener et al. (1996) 
Forssman, Henriksson, Johannsson, Lindval, & Lundin (1976) 
Havanka-Kanniainen, Hokkanen, & Myllyla (1988) 
Johnson, Hornabrook, & Lambie (1986) 
Kangasniemi & Hedman (1984) 
Kangasniemi, Nyrke, Lang, & Petersen (1983) 
Kjaersgard Rassmussen, Holt Larsen, Borg, Soelberg Sorensen, & Hansen (1994) 
Kuritzky & Hering (1987) 
Lucking, Oestreich, Schmidt, & Soyka ( 1988) 
Ludin (1989) 
Mathew (1981) 
Mikkelsen, Kjaersgaard Pedersen, & Christiansen (1986) 
Nadelmann, Phil, Stevens, & Saper (1986) 
Pita, Higueras, Bolanos, Perez, & Mundo (1977) 
Pradalier et al. ( 1989) 
Rao, Das, Taraknath, & Sarma (2000) 
Rosen (1983) 
Sargent et al. (1985) 
Standness (1982) 
Stensrud & Sjaastad (1976) 
Tfelt-Hansen, Standnes, Kangasneimi, Hakkarainen & Olesen (1984) 
Weber & Reinmuth (1972) 
Wilderoe & Vigander (1974) 
Zeigler, Hurwitz, Preskorn, Hassanein, & Seim (1993) 
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Table 2 
Primary Articles That Were Included in the Meta-Analysis for Flunarizine 
Authors 
Al Deeb, Biary, Bahou, Al Jabeeri, & Khoja (1992) 
Allias et al. (2002) 
Bussone et al. (1987) 
Freitag, Diamond, & Diamond (1991) 
Frenken & Nuijten (1984) 
Lamsudin & Sadjimin ( 1993) 
Louis (1981) 
Louis & Spierings ( 1982) 
Lucking, Oestreich, Schmidt, & Soyka (1988) 
Ludin (1989) 
Mentenopolous, Manafi, Logothetis, & Bostantzoulou (1985) 
N uti et al. ( 1996) 
Pini, Ferrari, Guidetti, Galetti, & Sternieri (1985) 
Rascol, Montastruc, & Rascol (1985) 
Sorensen, Hansen, & Olesen (1986) 
Sorensen & The Danish Migraine Study Group (1989) 
Thomas, Behari, & Ahuja (1991) 
Table 3 
45 
Primary Articles That Were Included in the Meta-Analysis for Divalproex Sodium Studies 
Authors 
Jensen, Brink, & Olesen (1994) 
Kaniecki ( 1997) 
Kinze et al. (2001) 
Klapper ( 1997) 
Lenaerts, Bastings, Sianard, & Schoenen ( 1996) 
Mathew et al. ( 1995) 
Rothrock, Kelly, Brody , & Golbeck (1994) 
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Table 4 
Primary Articles that Were Included in the Meta-Analysis on Nonpharmacological 
Treatments 
Combined 
therapies 
Thermal Relaxation 
Author biofeedback therapy EMG TBF+ 
Blanchard , Andrasik, Neff, Arena, et x x 
al. (1982) 
Blanchard et al. (1985a) x 
Blanchard et al. (1985b) x 
Blanchard , Appelbaum, Nicholson, et x x 
al. (1990) 
Blanchard , Appelbaum, Radnitz , et x x x 
al. (1990) 
Blanchard , Nicholson , et al. (1991) x 
Blanchard et al. (1997) x 
Blanchard et al. (1978) x x 
Daly, Donn, Galliher, & Zimmerman x x x 
(1983) 
Gauthier, Lacroix , Cote, Doyon, & x 
Drolet (1985) 
Gauthier, Cote, & French (1994) x 
Holroyd et al. (1995) x 
Holroyd et al. (1988) x 
Jurish et al. (1983) x 
(table continues) 
Author 
Lake, Raney, & Papsdorf (1979) 
Largen, Mathew, Dobbins, & 
Claghorn ( 1981) 
McGrady, Wauquier, McNiel, & 
Gerard (1994) 
Mullinix, Norton, Hack, & Fishman 
(1978) 
Wauquier, McGrady , Aloe, Klauser , 
& Collins (1995) 
Combined 
therapies 
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Thermal Relaxation ---- ----
biofeedback therapy EMG 
x 
x 
x 
x 
x 
x 
TBF+ 
x 
overall score was .88, indicating that a high level of agreement between raters. This 
suggests that this measure can be reliably used by different raters. 
Analysis 
After data were collected from primary studies, a variety of procedures were used 
to evaluate the data for use in this meta-analysis. Analysis procedures will be described in 
the following order: (a) standard effect sizes for continuous data, (b) odds ratios for binary 
data, ( c) inclusion of cross-over studies for continuous and binary data, ( d) homogeneity 
model, and ( e) inferential statistics used . 
Effect Sizes for Articles Reporting 
Continuous Data 
Data from primary articles that are expressed in the form of continuous outcomes 
use means, standard deviations, and inferential statistics to report the outcomes of the 
study. When this is the case the standardized mean differences were calculated. Glass, 
McGaw, and Smith (1981) report procedures for this calculation in its simplest fomi as 
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g = (Mtreatment) - (M control )/SD pooled. Hedges and Olkin (1985) reported that this 
formula results in a small sample bias and, thus , this meta-analysis used d as the estimator 
of effect size (d= g(l - 3/4m - 1)), where m equals the degrees of freedom based on the 
pooled standard deviation calculation. Throughout this meta-analysis , standard 
procedures for estimating effect sizes were used as recommended by Hedges and Olkin. 
All standard deviations used in calculations are pooled. 
A key statistical issue in examining continuous data on migraine prophylaxis is 
determining the appropriate statistical formula to use when paired data are presented in 
the primary article. Most research on migraine prophylactics use a pre-post design, even if 
a control/placebo group is being used. Formulas exist for calculating a paired t effect size 
given the N, SD and paired t-statistic. However, this type of data (i.e., the N, SD and 
paired !-statistic) is rarely presented in peer-reviewed journal articles. Dunlop , Cortina, 
V aslow and Burke ( 1996) convincingly argued that the calculation for the standardized 
mean difference using the independent t-test formula value can be substituted in lieu of the 
paired-data formula. They argued that if the paired t test is used ( which corrects for the 
amount of correlation between the measures), the resulting ES estimate will be an 
overestimate of the actual ES . Therefore, this meta-analysis employed the more 
conservative independent t-test method when presented with paired data. 
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Given the variety of statistical information provided in the primary articles 
reporting continuous data, a hierarchy was developed to aid in consistent decision making 
about statistical selection. Examples of all the below calculations can be found in 
Appendix F. All continuous data calculations were performed with the aide of Meta-Stat 
® computer program. 
Decision Making About Effect Size Estimate 
1. The "premiere" statistic is the standardized mean difference between two 
independent samples . 
2. If data to calculate the above is not provided , then an effect size estimate from 
t, F, Z, or r will be used. 
3. If 1 or 2 cannot be calculated , then an exact p estimate will be used to calculate 
a Tscore . 
4. If the groups being compared are a baseline average of several treatments , then 
a pooled standard deviation will be calculated and the groups will be compared as if 
independent. 
5. A z-score conversion of percent improved will be calculated if appropriate data 
are provided. A z-score conversion was only calculated on single-population studies if 
there were three discrete assessment periods (a baseline, a placebo, and an active 
treatment). Odds ratios are to be calculated in preference to z-score conversion if data are 
present. 
Effect Sizes for Articles Reporting 
Binary Data 
The second type of data available in primary articles on migraine prophylaxis is 
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binary data. Medical research in the area of migraine headache commonly divides outcome 
data into binary form. That is, researchers often report data for "responders" (those who 
achieved a 50% reduction on some measure through treatment) and "nonresponders" 
(those who achieved less than 50% reduction on some measure through treatment). This is 
valuable data primarily because individuals are used as their own control, which lends itself 
to a broader range of statistical analysis. The reduction of headache indices at the 50% 
level is considered to be a clinically significant change and is used industrywide. The 
procedure of reporting responder results also has draw backs. Namely, the data are 
artificially dichotomized which results in the loss of exact data in some cases. That is, 
those subjects who respond at the 48% level are treated the same as those who respond at 
the 2% level. Likewise, those who respond at the 55% level are treated the same as those 
who respond at the 100% level. Thus, binary data is less exact than continuous data and 
carries less interpretive weight than continuous data. In the present study, more 
confidence is placed in results obtained from continuous data (because they are considered 
to be more representative of the primary findings) than in results gained from the binary 
effect sizes. 
Given that many studies initially selected for inclusion in this meta-analysis 
reported binary data, a standardization statistic is needed so that it can be compared to 
other studies. There are three alternative measures that are generally considered for 
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standardizing binary outcome: the odds ratio, the risk difference, and the risk ratio. The 
three statistics vary based on the measurement and use of absolute size difference and 
relative size difference of treatment effect. The current meta-analysis reports binary data in 
the form of odds ratio's (OR). Deeks (2002) reported that odds ratios are typically used in 
case-control studies when disease prevalence is not known. In the current research the 
baseline prevalence is unknown (i.e., the placebo or control rate of spontaneous 
remission). Deeks reported that the use of relative risk ratios or risk difference ratios, 
while potentially more intuitive, alters the effect measure by entering a false prevalence 
rate that is not known and would "obviously be wrong, so odds ratios are the ideal" (p. 
1598). The OR has a neutral statistic of "I," which indicates the odds ofreceiving 
benefit/harm from the treatment is equal in both the control and the treatment group. As 
the numbers approach infinity or "O," they indicate what the odds of benefit/harm are for 
one group in comparison to the other. Thus, a .73 OR indicates that you have .73 ti.rnes 
higher chance of getting benefit/harm in the first treatment than in the second. Values over 
one simply indicate that the benefit/harm chance is higher in the second group than it is in 
the first. If confidence intervals encompass the value of 1, then the chance of receiving 
benefit/harm from the two treatments are considered to be nearly equal. When researchers 
report OR they typically maintain one treatment group as the "anchor," in this study the 
control was always the second treatment group, indicating that higher scores favor the 
active treatment. 
Once OR were calculated they were converted to Log-odds or the natural 
logarithm of the OR. This converts the metric from an asymmetrical distribution that is 
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distributed between zero and infinity to a symmetric statistic running from minus infinity to 
plus infinity, with zero being the neutral value. This makes it easier to compare negative 
with positive associations. And it is necessary in order to aggregate a total effect (Deeks, 
2002). All OR were calculated with the assistance ofMetaAnalysis 3.0 ® by Alan Chang 
2001. Examples of an OR calculation can be found in Appendix F. 
Inclusion of Cross-Over Design Studies 
In the past many authors of meta-analytic studies have chosen to disregard studies 
that employ a cross-over design. A preliminary review indicated that 82% of meta-
analyses at the Cochrane Controlled Trials Registrar do not include cross-over design 
studies (Elbourne, Altman, Higgins, et al., 2002). This practice has been largely founded 
on poor reporting of data in cross-over trials. Many primary studies choose to report 
grand mean and standard deviations for treatment groups. This disregards the fact that 
patients are their own controls, each patient has received multiple treatments, and means 
are actually change scores and not independent group means. Thus, many conducting 
meta-analyses have chosen to ignore data from cross-over trials. 
Excluding cross-over data has come under fire recently due to the exclusion of 
large numbers of studies that compare treatments ( e.g., Curtin, Altman, & Elbourne, 2002; 
Elbourne et al., 2002). Theoretically, cross-over data is more robust than parallel data. In 
addition, cross-over designs often compare two active treatments to each other. 
Chambless and Hollon (1998) suggested studies that compare a new treatment to an 
established treatment can be considered the premier type of efficacy research. Thus, the 
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exclusion of cross-over design studies would lead to the exclusion of studies that are both 
statistically and theoretically important. Consequently, it was determined that the present 
study would include cross-over designs. 
How cross-over designs should be included in a meta-analysis is a matter of 
statistical debate. Three general options are available: (a) use pooled data from cross-over 
studies and treat them as if the datum came from a parallel design ( which results in an 
underestimation of effect) ; (b) use data only from one phase of the cross-over design thus 
making the study a parallel one (which results in an inflated Type 1 error); (c) include only 
studies that report individual change scores , calculate the pooled variance estimate, and 
calculate paired statistics effect sizes to adjust for the cross-over design (results in the loss 
of a large number of studies). 
The current meta-analysis employed a combined approach described in Elbourne et 
al. (2002) for articles reporting continuous data. Primary studies that listed data on 
individual patients or accurately provided paired data analysis were used to generate 
Pearson's r statistics-for between group correlations (accounting for the fact that in a 
cross-over design individuals are their own controls). The lowest correlation found among 
primary articles was then substituted into the effect size calculation for the other cross-
over design studies within the same treatment type. An example of the substitution of a 
correlation into a calculation for a standardized mean difference effect size can be found in 
Appendix F. 
Odds ratios require a different strategy when cross-over studies are included. 
Given that OR already take into account the odds for a single individual on multiple 
treatments, correlations adjustments have not been found to alter the estimate of the 
treatment odds (Elbourne et al., 2002) . Articles reporting binary data that were summed 
across trial periods were used as if they were parallel. 
Homogeneity Model 
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The selection of the appropriate summary statistic that represents the average 
treatment effect size and corresponding confidence intervals for the meta-analysis is based 
primarily on the issue of variance. Standard procedures for analyzing results of meta-
analyses have traditionally been based on the assumption that there is one true treatment 
effect being described by the meta-analysis (Fixed Effects Model). Under the Fixed Effects 
Model (FEM) there is an assumption that any variation that occurs among study effect 
sizes is caused by study variance accounted for by sampling error, patient characteristics, 
or study characteristics (i.e. , variance with-in the study). Summary statistics based on this 
assumption assume that each study in the meta-analysis has the same underlying effect 
(Brockwell & Gordon, 2001). That is, the FEM assumes that there is little study-to-study 
variation and that the selection of studies is homogeneous. 
In contrast the Random Effects Model (REM) assumes that the studies represent a 
heterogeneous sample with two sources of variance--the variance within the study and the 
variance between the studies. The addition of the between-study variation to the model 
indicates that the primary studies each contribute (potentially uniquely) to the true effect. 
Thus, the summary statistic becomes an indication of the general treatment effect that 
centers around the true effect (Brockwell & Gordon, 200 I; Glasziou & Sanders, 2002). 
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The two separate sources of variance allow for the assumption that the primary article 
effect sizes are independent and normally distributed (Brockwell & Gordon). The REM 
introduces an estimation of between study variance into all weighted averages to account 
for a random model. 
The choice between the two models can be made by testing for heterogeneity 
between the individual effect sizes. The amount of heterogeneity between studies can be 
tested through the use of the statistic defined by Cochran (1937) , which in practical form 
IS: 
~ " ")2 Q,v = w;(Y;- µ . 
Where w = the inverse of the variance (or weight), Yi = the effect of each trial, and µ = 
the overall effect estimated from the meta- analysis. Thus, the calculation sums together 
the weighted differences between overall effect size and the individual study effect sizes 
(for an example of a calculation of a Cochran's Q see Appendix F). As the value of Qw 
increases (results can range from zero to infinity), it indicates more study to study 
variation. Cochran's Q is typically reported with a p value to indicate if heterogeneity is 
considered to be more than would be expected by random sampling error. Thus, a 
significant p value indicates that more heterogeneity exists than would be expected by 
chance. The current study calculated Cochrane's Q for each treatment type. However, it 
has been argued that the choice between FEM and REM should not be solely based on the 
Cochran's Q (Brockwell & Gordan; Chang, Watemaux, & Lipsitz, 2001). In addition, 
because this meta-analysis is comparing six separate treatments, it is important for a single 
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model to be used consistently across treatment types. Thus, the current meta-analysis 
applied a REM to all summary statistics. The FEM has been shown to have too narrow of 
confidence intervals and to over-estimate the '"treatment effect" being described by the 
meta-analyses. Larger confidence intervals and smaller effect sizes are likely to be 
produced when using this model than when using the FEM (Brockwell & Gordan, 2001; 
Curtin et al., 2002). The calculation of the Cochrans Q and summary statistics in the REM 
model were calculated with the assistance ofMetaAnalysis 3.0 ® computer program 
developed by AJan Chang 2001 . 
Inferential Statistics 
Rosenthal's file drawer calculation was calculated for each treatment study. The 
file drawer phenomenon refers to a well-known publication bias toward significant results. 
That is, publishers often only publish articles that report significant :findings. Articles that 
do not report significant :findings are often unpublished and left in the author's "file 
drawer." Meta-analyses that only consider published articles are then basing results on a 
biased sample. The Rosenthal's file drawer calculation is considered a rough guide for 
determining the number of unpublished null :findings that would be needed to threaten the 
:findings of the meta-analysis on the published articles. Essentially, the Rosenthal's file 
drawer test indicates if a finding of a meta-analysis is robust enough to stand against null 
unpublished results. Each calculation is reported with the following: (a) an N, that 
represents the number of null studies it would take to threaten the finding;, (b) a "credible 
if' statement indicating that if the N is lower than the "credible if' number, then the 
findings may not be robust to the file drawer phenomenon; and ( c) a probability level 
based on a z score indicating the probability of finding a similar result by chance. 
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Regression analysis was used by treatment to identify study characteristics that 
correlated with treatment effects. Pearson product-moment correlations were run to 
identify significant associations between the study or sample characteristic and outcome. 
Comparison of summary statistics across treatments through both visual comparison and 
analysis of variance (ANOVA) were conducted to test for statistical differences between 
summary statistics. 
CHAPTERV 
RESULTS 
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The resuhs of the meta-analysis will be presented according to the following 
sections: (a) results for Propranonol, (b) results for Flunarizine, (c) results for Divalproex 
Sodium, (d) results for thermal biofeedback, (e) results for relaxation treatments, (f) 
results for combination treatments, and (g) comparisons between summary statistics for all 
treatments. 
Results for Propranonol 
Thirty-one effect sizes were calculated on a total of 30 studies for Propranonol 
treatment. One study, Lucking et al. (1988), reported data on two separate trials so two 
effect sizes were calculated from this study. Studies ranged in publication years from 1972 
to 2000. The meta-analysis on Propranonol included 3,247 total observations, with 1,987 
observations in the control group and 1,260 observation in the treatment group. Twenty-
three (74.2%) of the studies compared Propranonol to a placebo group. The other eight 
used a control group rather than a placebo group. Reduction in the frequency of headache 
was the most consistently reported outcome measure (27 of 31 ). Doses ranged from 60-
240 mg a day, with the mode being 180 mg a day. Modal active treatment length was 12 
weeks (range 4 to 52 weeks). Mean Jadad quality score was 3.22, mean study quality 
score was 2.48, mean mortality rate was 22%, and the study population was 74% female 
(mean). 
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Ten of the studies were parallel designs, the other 21 were cross-over designs. 
Three articles provided enough information to calculate the correlation between groups 
for cross:-over calculations. These were Borgensen et al. (1974) =.82; Mikkelsen et al. 
(1986) = .81; and Stensrud and Sjaastad (1976) = .74. The lowest correlation (.74) was 
substituted into the 18 other cross-over studies to account for the cross-over design issue. 
Twenty-five studies provided enough continuous data to calculate standardized 
mean differences. Odds ratios were calculated on the remaining six studies. Summary 
statistics are listed below in Table 5 by category. 
Regression analysis indicated that unbiased effect sizes varied systematically by 
study design type, with cross-over studies producing significantly higher effect sizes than 
Table 5 
Findings for Propranolol 
Statistic 
Q statistic 
REM summary effect size 
REM summary CI (95%) 
Variance 
Standard deviation 
Rosenthal's file drawer 
Continuous data 
54.2989 p = 0.0004 
SMD = .68 
(.54 - .81) 
0.0044 
0.06667 
1122 
Credible threat if< 13 5 
p = 0.0000 
z = 13.2711 
Binary data 
16.4264 p = 0.0057 
ln(OR) = 1.58 
(1.08 - 2.07) 
0.643 
0.2536 
146 
Credible threat if< 40 
p = 0.0000 
z = 9.85 
Note. SMD = Overall standardized mean difference score; ln(OR) = Overall natural 
logarithm of the odds ratio. 
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parallel design studies (R2= .238, F= 7.89,p =.011). A significant correlation was noted 
between unbiased effect size and study design type (r = .514), indicating that there is a 
significant correlation between study design ( cross-over or parallel) and effect size. See 
Appendix G for full reporting of regression analyses and partial correlations. 
Results for Flunarizine 
Eighteen effect sizes were calculated on a total of 17 studies for Flunarizine 
treatment. One study, Lucking et al. ( 1988), reported on two separate trials so two effect 
sizes were calculated from this study. Studies ranged in publication years from 1982 to 
2002 . The meta-analysis on Flunarizine included 1, 702 total observations. With 1,030 
observations in the control group and 672 observation in the treatment group. Eight 
(44.4%) of the studies compared Flunarizine to a placebo group. The other 10 used a 
control group or baseline rather than a placebo group. Frequency measures were the most 
consistently reported measure ( 15 of 18). Doses ranged from 5-10 mg a day with the 
mode being 5 mg a day. Modal active treatment length was 14 weeks (range was 4-24 
weeks). Mean Jadad quality scores was 2.83, mean study quality score was 2.50, mean 
mortality rate was 13% and the study population was 75% female (mean). 
Fifteen of the studies were parallel designs, the other two were cross-over designs. 
Fifteen studies provided enough continuous data to calculate standardized mean 
differences. Odds ratios were calculated on the remaining three studies. Summary statistics 
are listed below in Table 6 by category. 
Table 6 
Findings for Flunarizine 
Statistic Continuous data Binary data 
Q statistic 30.9889 p = 0.0056 1.6110 p = 0.4469 
REM summary effect size SMD= .68 ln(OR) = 1.4942 
REM summary CI Interval (95%) (.53-.83) (0.73-2.25) 
Variance 0.0057 0.152 
Standard deviation 0.075 0.39 
Rosenthal's file drawer 496 8 
Credible threat if < 85 Credible threat if < 25 
p = 0.0000 p = 0.0001 
z = 11.4606 z = 3.7247 
Note. SMD = Overall standardized mean difference score; ln(OR) = Overall natural 
logarithm of the odds ratio 
Regression analysis indicated that unbiased effect sizes varied systematically by 
treatment length, with treatments that were longer producing significantly higher effect 
sizes (R2 = .587; F = 17.07,p =.001). A significant correlation was noted between 
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unbiased effect size and treatment length (r = . 733). See Appendix H for full reporting of 
regression analyses and partial correlations. 
Results for Divalproex Sodium 
Seven effect sizes were calculated on Divalproex Sodium treatment. Studies ranged 
in publication years from 1991 to 2001. The meta-analysis on Divalproex Sodium included 
553 total observations, with 213 observations in the control group and 340 observation in 
the treatment group. Six (85.7%) of the studies compared Divalproex Sodium to a 
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placebo group. The remaining study used a control group rather than a placebo group. All 
studies reported frequency outcome measures. Doses ranged from 500-2000 mg a day. 
Doses were typically individually adjusted to be within optimal serum levels (50-
lOOmg/ml). Modal active treatment length was 12 weeks (range 6 to 24 weeks). Mean 
Jadad quality scores was 2.57, mean study quality score was 2.14, mean mortality rate was 
16.2%, and the study population mean was 83.7% female. 
Five studies were of a parallel design and the other two studies were cross-over 
designs. None of the articles provided enough information to calculate the correlation 
between groups for cross-over calculations. Therefore, one cross-over study that provided 
continuous data (Hering & Kuritzky, 1992) was discarded. 
One parallel design study provided enough continuous data to calculate standardized 
mean differences (Kinze et al., 2001). The standardized mean difference was 1.66. A 
meta-analysis was not performed on this single effect size. Odds ratios were calculated on 
the remaining six studies. Summary statistics are listed below in Table 7. 
Regression analysis indicated that unbiased effect sizes did not systematically vary 
by study design type, treatment length, quality scores, or by type of control groups used 
(R2 = 1.00). No significant correlations were noted between any variable and unbiased 
effect size. See Appendix I for full reporting of regression analysis and partial correlations. 
Results for Thermal Biofeedback 
Eighteen effect sizes were calculated on 15 studies for thermal biofeedback. 
Table 7 
Findings for Divalproex Sodium 
Statistic 
Q statistic 
REM summary effect size 
REM summary CI (95%) 
Variance 
Standard deviation 
Rosenthal's file drawer 
Binary data 
4.5794 p = 0.4693 
ln(OR) = 1.65 
(1.20-2.11) 
0.0535 
0.2314 
80 
Credible threat if< 40 
p = 0.0000 
z = 7.40 
Note. ln(OR) = Overall natural logarithm of the odds ratio. 
Three studies (Blanchard et al., 1982, 1991; Jurish et al., 1983), were multi-arm studies 
that allowed for two calculations to be made from each study. The thermal biofeedback 
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area of treatment can be broken into two protocols of treatment , one that includes explicit 
relaxation training and one that does not. In this sample 14 effect sizes were calculated 
from studies that explicitly taught some version of relaxation training ( e.g., progressive 
muscle relaxation, autogenic training) and 6 effect sizes were calculated from studies that 
did not. Analysis of the findings indicate that results did not significantly vary with the 
addition of relaxation to the standard thermal biofeedback protocol. Thus, results are 
aggregated across these two categories. 
Studies ranged in publication years from 1978 to 1997. The meta-analysis on 
thermal biofeedback included 576 total observations , with 261 observations in the control 
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group, and 315 observations in the treatment group. Fourteen (70%) of the studies 
compared thermal biofeedback to another treatment. The other four studies compared the 
treatment to a wait list group rather than an alternate treatment group. Ten effect sizes 
were calculated from studies that compared thermal biofeedback to a control group. The 
other eight effect sizes were calculated from within-group comparisons based on studies 
that compared multiple nonpharmacological treatments. Effect sizes were calculated 
separately for within-group studies and between group studies to identify if effects were 
significantly different by study design. Studies that were compared to control groups had 
an average effect size of .66 and studies that were comparison treatment designs with pre-
post measures averaged an effect size of .64. This suggests that comparison treatment 
studies and controlled outcome studies for migraine prophylaxis are measuring a similar 
effect . Thus , these two groups were summed for summary effect size calculation. 
Headache Index measures were the most consistently reported measure (14 of 18). 
Number of sessions ranged from 2 to 22 with the mode being 12. Modal treatment length 
was 6 weeks (range 5 to 32 weeks). Mean Jadad quality scores was 1.66, mean study 
quality score was 2.66, mean mortality rate was 15.22% , and the study population was 
81 % female (mean). 
All eighteen effect sizes were derived from parallel designs and fourteen studies 
provided enough continuous data to calculate standardized mean differences. Odds ratios 
were calculated on the remaining four studies. Summary statistics are listed below in 
Table 8 by category. 
Table 8 
Findings for Thermal Biofeedback 
Statistic 
Q statistic 
REM summary effect size 
REM summary CI (95%) 
Variance 
Standard deviation 
Rosenthal's file drawer 
Continuous data 
2.8813 p = 0.9983 
SMD = .60 
(.40-.79) 
0.0098 
0.09899 
121 
Credible threat if < 80 
p = 0.0000 
z = 6.0671 
Binary data 
3.1559 p = 0.3682 
ln(OR) = 1.24 
(1.08-2.07) 
0.148 
0.03856 
8 
Credible threat if < 30 
p = 0.0004 
z = 3.3416 
Note. SMD = Overall standardized mean difference score; ln(OR) = Overall natural 
logarithm of the odds ratio. 
Regression analysis indicated that unbiased effect sizes did not vary systematically 
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(R2 = .928, F = 3876 , p = .146). Variance for both binary and continuous data is very low 
indicating that effect sizes were fairly uniform and did not vary by study characteristics. 
No significant correlations were noted between unbiased effect size and any study 
variable. See Appendix J for regression analyses and partial correlation tables. 
Results for Relaxation Therapy 
Five effect sizes were calculated for relaxation therapy. Treatments for relaxation 
therapy included progressive muscle relaxation, autogenic training, and meditation. 
Studies ranged in publication years from 1978 to 1990 (none after 1990 qualified for 
inclusion in the meta-analysis). The meta-analysis on relaxation therapy included 186 
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total observations, with 99 observations in the control group and 87 observations in the 
treatment group. All five studies compared relaxation therapy to another treatment. Four 
effect sizes were calculated from studies that compared thermal biofeedback to a control 
group, while the other effect size was calculated from with-in group comparisons. 
Headache Index measures were the most consistently reported measure (4 of 5). Number 
of sessions ranged from 8 to 16, with the mode being 9. Modal treatment length was eight 
weeks (range 5-37 weeks). Mean Jadad quality score was 1.83, mean study quality score 
was 2. 81, mean mortality rate was 13. 8%, and the study population was 81 % female 
(mean). 
All effect sizes were derived from parallel designs. Four of five studies provided 
enough continuous data to calculate standardized mean differences. An OR was calculated 
on the remaining study. The OR for Daly et al. (1983) was 4.5584 with a confidence 
interval of (0.88 to 23.37). The Log Odd was 1.51. Continuous data summary statistics 
are listed in Table 9 below. Partial correlations for relaxations treatments can be found in 
Appendix K. 
Due to the small number or studies included in the meta-analysis a regression 
analysis and partial correlations were not conducted. 
Results for Combination Therapies 
The results for the combination therapies include two major treatment categories: 
EMG biofeedback and thermal biofeedback plus relaxation plus cognitive therapy (TBF + 
R + Cog). Results will be presented on EMG biofeedback and then on TBF + R + Cog. 
Table 9 
Findings for Relaxation Therapies 
Statistic 
Q statistic 
REM summary effect size 
REM summary CI (95%) 
Variance 
Standard deviation 
Rosenthal's file drawer 
Continuous data 
6.1586 p = 0.9770 
SMD = .75 
(.37 - 1.13) 
0.0375 
0.1937 
17 
Credible threat if< 30 
p = 0.0000 
z = 4.4026 
Note. SMD = Overall standardized mean difference score. 
Results for EMG Biofeedback 
Combination Therapies 
The selection criteria for EMG biofeedback resulted in a low number of studies 
being kept for inclusion. Five different studies were identified for inclusion. Studies that 
met the inclusion criteria for EMG biofeedback ranged in publication years from 1971 to 
1994. The meta-analysis on EMG biofeedback included 97 total observations, with 51 
observations in the control group and 46 observations in the treatment group. Three 
(60%) of the studies compared EMG biofeedback to another treatment. The other two 
studies compared the treatment to a wait list group rather than to an alternate treatment 
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group. Four effect sizes were calculated from studies that compared EMG biofeedback to 
a control group, while the other effect size was calculated from with-in group 
comparisons. Headache Index measures were reported in three of five studies whereas 
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frequency measures were reported in two studies. Number of sessions ranged from 8 to 16 
with the mode being 12. Modal treatment length was 5 weeks (range 5-16 weeks). Mean 
Jadad quality scores was 1.45, mean study quality score was 2.62, mean mortality rate was 
15.75%, and the study population was 88% female (mean). All effect sizes were derived 
from parallel designs. 
A total of five effect sizes were calculated for EMG biofeedback. EMG biofeedback 
comes in two predominate forms; (a) EMG + Relax, or (b) treatment combined with 
thermal biofeedback and relaxation training (EMG + TBF + R). In this sample three effect 
sizes were calculated on EMG + TBF + R, and two effect sizes were calculated from 
studies on EMG + Relax. Analysis of these five studies showed that the two different 
protocols have distinctly different effect sizes and thus the results are reported separately. 
Odds ratios were calculated on all studies . The results shown in Table 10 are for the only 
two controlled studies available for EMG +Relax.Table 11 presents the findings for 
EMG+TBF+R. 
The following results are on the three controlled studies that reported treatment data 
on EMG + TBF + R. 
Regression analysis was not performed on these results due to the low study 
numbers. However , effect sizes were fairly uniform within treatment protocols indicating 
that effect sizes were unlikely to vary by study characteristic. 
Results for Thermal Biofeedback plus Relaxation 
Therapy plus Cognitive Therapy 
A total of four different studies were identified for inclusion. Studies that met the 
Table 10 
Findings for EMG + Relax 
Statistic 
Q statistic 
REM summary effect size 
REM summary CI (95%) 
Variance 
Standard deviation 
Rosenthal's file drawer 
Binary data 
0.8119 p = 0.3675 
ln(OR) = 2.47 
(4.0-.93) 
0.6184 
0.786 
4 
Credible theat if < 20 
p = 0.0005 
z = 3.2693 
Note. ln(OR) = Overall natural logarithm of the odds ratio. 
Table 11 
Findings for EMG + TBF + R 
Statistic 
Q statistic 
REM summary effect size 
REM summary CI (95%) 
Variance 
Standard deviation 
Rosenthal's file drawer 
Binary data 
0.0086 p = 0.9957 
ln(OR) = 1.1064 
(2.13-.075) 
0.2765 
0.526 
1 
Credible threat if< 20 
p = 0.0190 
z = 2.0759 
Note. ln(OR) = Overall natural logarithm of the odds ratio . 
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inclusion criteria for TBF + R + Cog ranged in publication years from 1979 to 1990. The 
meta-analysis on TBF + R + Cot included 112 total observations, with 49 observations in 
the control group and 63 observations in the treatment group. All of the studies compared 
TBF + R + Cog to another treatment. Three effect sizes were calculated from studies that 
compared TBF + R + Cog to a control group, while the other effect size was calculated 
from with-in group comparisons. Headache Index measures were reported in two of four 
studies , frequency measures in two of four studies. Number of sessions ranged from 5 to 
18, with the mode being 5. Modal treatment length was five weeks (range 5 to 12 weeks). 
Mean Jadad quality score was 1. 75, mean study quality score was 2.50 , mean mortality 
rate was 14.25%, and the study population was 76% female (mean). 
All effect sizes were derived from parallel designs. Three of four studies provided 
enough continuous data to calculate standardized mean differences. An OR was calculated 
on the remaining study. The OR for Lake et al. (1979) was 2.0370 with a confidence 
interval of(0.18-21.94). The Log (OR) was 0.71. Continuous data summary statistics are 
listed in Table 12 below. 
Due to the small number of studies included in the meta-analysis, a regression 
analysis and correlation analysis was not conducted. 
Results of Comparisons Between 
Summary Statistics 
Results for comparisons between meta-analyses will be presented in two ways. First, 
results are presented in table format for visual comparison. Deeks (2002) suggested that if 
Table 12 
Findings for TBF + R + Cog 
Statistic 
Q statistic 
REM swnmary effect size 
REM swnmary CI (95%) 
Variance 
Standard deviation 
Rosenthal's file drawer 
Continuous data 
1.1431 p = 0.5647 
SMD = 0.7260 
(1.13-.31) 
0.0442 
0.2102 
6 
Credible threat if < 25 
p= 0.0005 
z= 3.3080 
Note. SMD = Overall standardized mean difference score. 
71 
summary statistics fall within each others' confidence intervals then treatments are roughly 
equal. Thus, the effect sizes for treatments with more than one continuous outcome are 
presented in Table 13. Then, results of an AN OVA (Table 14) conducted on the summary 
statistics are reported . The summary results for ln(OR) data collected on treatments with 
more than one binary outcome are then reported in Table 15, with ANOVA results in 
Table 16. 
Excluded in the swnmary analysis is the single continuous effect size found for 
Divalproex Sodium ( d = 1.66) and the single OR found for relaxation therapies 
(In (OR)= 1.51) and TBF + R + Cog (ln (OR)= 0.71). Because these are single effect 
sizes they do not represent a body of literature and, thus, are not included. 
It should be noted that due to the nature of the two different types of data 
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Table 13 
Summary Statistics for Continuous Outcomes 
REM summary 
effect size 95% confidence 
Treatment N (SDM) interval 
Propranolol 25 0.68 .54- .81 
Flunarizine 15 0.68 .53- .83 
Thermal biofeedback 14 0.60 .40- .79 
Relaxation therapy 4 0.75 .37-1.13 
Combination therapy 
TBF+R+Cog 3 0.72 .31-1.13 
Table 14 
ANOVAfor Continuous Summary Statistics 
Sum of 
squares df variance F p value 
Between-group 0.105 4 0.03 2.9024 0.0297 
Within-group 0.51 56 0.01 
Total 0.61 60 
( continuous and binary) not all outcomes could be directly compared to each another. 
Only one type of effect size was calculated for each study. If the researchers provided 
binary data, an OR was calculated; if continuous data were provided, a standardized mean 
difference effect size was calculated . Therefore, in some cases a treatment category ( e.g., 
Propranolol) will have some OR effect sizes and some standardized mean difference effect 
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Table 15 
Summary Statistics for Binary Outcomes 
REM summary 
effect size 
Treatment N ln(OR) 95% confidence interval 
Propranonol 6 1.58 1.08-2.07 
Flunarizine 3 1.49 .73 -2.25 
Divalproex Sodium 5 1.65 1.20-2.11 
Thermal biofeedback 64 1.24 1.08-2.07 
Combination therapy 
EMG+Relax 2 2.47 .93-4.0 
EMG+ TBF + Relax 3 1.11 .075-2.13 
Table 16 
ANOVAfor Binary Summary Statistics 
Sum of 
Source squares df variance F p value 
Between-group 2.29 5 0.46 3.1775 0.0314 
Within-group 2.60 18 0.14 
Total 4.89 23 
s12es. Both types of data were found for Propranolol, Flunarizine, and thermal 
biofeedback. Binary data only were found for Divalproex Sodium, EMG biofeedback plus 
Relaxation, and EMG biofeedback plus thermal biofeedback plus relaxation therapy. Only 
continuous data were used to calculate effect sizes for relaxation therapy and thermal 
biofeedback plus relaxation plus cognitive therapy. The result of including two types of 
data is that the outcomes for some treatments types are not directly compared to other 
treatment types. For example, Divalproex Sodium has one continuous effect size 
(mentioned above) that was excluded and six binary effect sizes. The six binary effect 
sizes are summed and reported in Table 15, resulting in Divalproex Sodium only being 
compared to the other treatments that have binary outcomes. This excludes relaxation 
therapy, which reported five continuous outcomes and is summed in Table 13. Thus, 
Divalproex Sodium and relaxation therapy are not directly compared. 
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Indirect comparisons can be made by using the treatments that provided both types 
of data. For example, Divalproex Sodium (binary) and relaxation therapy (continuous) can 
be indirectly compared by directly comparing each to Propranolol (which provides both 
binary and continuous outcomes). Through visual inspection it can be determined that 
Propranolol and Divalproex Sodium have similar effect sizes and that Propranolol and 
relaxation therapy have similar effect sizes; thus, Divalproex Sodium and relaxation 
therapy are likely to have the similar effect sizes. 
The results from the one-way ANOV A to compare continuous summary effect sizes 
revealed a significant effect F= 2.902,p = .0297 (see Table 14). Post hoc Bonferroni 
adjusted comparisons revealed no significant individual group comparisons (see Table LI 
in Appendix L). 
The results from the one- way ANOVA to compare groups revealed a significant 
effect F= 3.1775,p = .0314 (see Table 16). Post hoc Bonferroni adjusted comparisons 
revealed no significant individual group comparisons (see Table L2 in Appendix L). 
CHAPTER VI 
DISCUSSION 
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The current meta-analysis was conducted to answer four questions: (a) How do 
the effectiveness rates of treatments compare to each other and between groups 
(pharmacological and nonpharmacological)? (b)What sample characteristics are 
significantly correlated with outcomes? (c) Do outcomes vary if broken into two levels of 
empirical evidence? ( d) What information is available regarding short and long term 
effectiveness rates for pharmacological and nonpharmacological studies? Each of these 
questions will be addressed in tum. A discussion of the practical uses of these findings 
follows. Then, limitations of the current findings will be discussed. Finally, suggestions for 
future research in the area of migraine headache are proposed. 
How the Effectiveness Rates of Treatments Compare 
to Each Other and Between Groups 
The results of the present meta-analysis suggest that five of the six evaluated 
treatments have very similar effect sizes. In addition, the findings suggest that three of the 
summary effect sizes (EMG biofeedback, relaxation therapy, and thermal biofeedback plus 
cognitive therapy) are tentative due to a serious threats to validity from the file drawer 
phenomenon. The evidence for these conclusions are reviewed below in the following 
order (a) visual comparison of effect sizes, (b) Rosenthal's file drawer findings, (c) 
inferential statistical findings, ( d) findings for EMG biofeedback plus relaxation, ( e) 
findings for EMO biofeedback plus thermal biofeedback plus relaxation, and (f) the 
summary of the outcomes and possible explanations for findings. 
Comparisons by Visual Analysis 
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The current meta-analysis compiled treatment effectiveness data on six 
prophylactic treatments for migraine. The summary statistics presented represent the 
results for the reduction of frequency or headache index for each respective treatment of 
migraine headache. Summary statistics for continuous data range from .60 to .75. The 
lowest summary effect size was found for thermal biofeedback treatment and the highest 
summary effect size was found for relaxation therapy. All other treatments (Propranonol, 
Flunarizine, Divalproex Sodium, and mixed treatments) had summary effect sizes that fell 
within this range . All summary statistics fall within each other's confidence interval. 
According to Gall, Borg , and Gall (1996), these effect sizes are in the large range of 
treatment effectiveness. 
Evaluation of the binary summary statistics also show two patterns. The majority 
of the log (OR) statistics fall in a narrow range of effect sizes (1.49-1.65). Again, those 
effect sizes that were clustered together all fell within one another's confidence intervals. 
There are two exceptions for this pattern and they both involve EMO biofeedback. The 
EMO biofeedback treatment has two protocols, one that includes thermal biofeedback and 
one that does not. Analysis of the results revealed that when the protocols were split, the 
EMO biofeedback treatment that included thermal biofeedback was low, log (OR)= 1.10, 
and the EMO biofeedback that did not include thermal biofeedback was substantially 
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higher, log (OR)= 2.47. The findings for EMG biofeedback represent the only effect size 
that appears to be significantly different from the other treatments analyzed. Possible 
reasons for all of these findings will be presented below following the discussion of the 
inferential statistical results. 
Rosenthal's File Drawer 
Rosenthal's file drawer ratings for each treatment indicates that the file drawer 
threat is a valid threat to the following treatments, Flunarizine (binary data only), thermal 
biofeedback (binary data only), relaxation treatments, EMG biofeedback plus relaxation, 
EMG biofeedback plus thermal biofeedback plus relaxation, and thermal biofeedback plus 
relaxation plus cognitive therapy. The first two treatments, Flunarizine and thermal 
biofeedback, are not seriously threatened by the file drawer phenomenon because the 
continuous data provides more than enough findings to support the conclusions in the 
published research. Therefore, the results for Propranonol, Flunarizine, Divalproex 
Sodium, and thermal biofeedback are considered to be stable results that could not be 
easily threatened by nonpublished studies that show no difference between the treatments 
and control groups. 
However, the other treatment results (EMG treatments, relaxation treatments, and 
thermal biofeedback plus relaxation plus cognitive therapy) are potentially threatened by 
nonpublished studies that support the null hypothesis. Thus, less confidence can be placed 
in the findings for EMG treatments, relaxation treatments, and thermal biofeedback plus 
relaxation plus cognitive therapy. This is largely due to the small number of studies used 
to find the summary statistic in each of these treatments. Of particular concern are the 
results for the EMG biofeedback plus thermal biofeedback plus relaxation treatment that 
indicates that only one unpublished article (that finds support for the null hypothesis) 
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could be a valid threat to these results. So, while the present findings are suggestive of the 
basic trend for these treatments, there is not enough data to form solid conclusions about 
their treatment effect without further replication of outcome findings. 
Comparisons by Inferential Statistics 
Inferential statistics were used to compare effect sizes to one another. ANOVA 
procedures were conducted to attempt to identify statistically significant differences 
between the summary statistics. Results from the ANOV A indicated that there was a 
significant difference between the summary statistics for both the continuous data (F = 
2.90 ;p = .029) and binary data (F = 3.l 7;p = .031). Post-hoc analysis with Bonferroni 
corrections were performed. None of the post-hoc analyses reached significance. This is 
likely due to the large number of comparisons that were conducted between the groups. 
By performing approximately 10 comparisons for each group of outcomes the significance 
value with Bonferroni correction becomes p < .005 (continuous) or p < 003. (binary). This 
is an extremely stringent test and these treatments did not reach the criterion. 
It should be noted that several authors warn that using inferential statistics is highly 
inappropriate for meta-analyses (e.g., Abrarni, Cohen, & Apollonia, 1988; Schmidt, 1992). 
They argue that the nature of effect sizes violate the assumptions of inferential statistics 
(i.e., they are not samples of the population, they are the population; they do not meet the 
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assumptions of normal distributions, etc.) . In addition, they report that inferential statistics 
are inappropriate for measurement based on the individual unit; effect sizes that are 
weighted (as are all summary statistics used under the random effects model) result in a 
statistic that is based on the individual. The current meta-analysis is likely to have been 
effected by these issues. In the present meta-analysis a specific population of interest was 
defined a priori (i.e., through the use of inclusionary rules such as migraine prophylactic 
studies that examined one of six treatments, providing enough data to calculate an effect 
size, etc.) . A systematic search strategy was used to attempt to obtain all studies that made 
up the defined population. As a result , the use of inferential statistics would be 
inappropriate in the current meta-analysis to the same extent that the efforts to obtain all 
articles were successful. Thus , the results of the ANOVA 's and post-hoc Bonferonni 
calculations in the current meta-analysis may be invalid due to assumption violations and 
should be interpreted with caution. 
EMG Biofeedback Plus Thermal Biofeedback 
The low ln (OR) summary statistic for EMG biofeedback plus thermal biofeedback 
is not as interpretively important as the meaning of this treatment's confidence interval. 
When a ln (OR) confidence interval encompasses zero it can represent that a treatment has 
no greater effect than the comparative treatment (in this case, a control group). It should 
be noted that the EMG biofeedback plus thermal biofeedback confidence interval is the 
only treatment that has a confidence interval that approaches zero (.075). If the true 
treatment effect for EMG biofeedback plus thermal biofeedback lies in the lower end of 
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the confidence interval, it would indicate that the odds of an individual having a successful 
outcome with this treatment may be equal to the odds of a placebo outcome. 
Statistically, the wide confidence interval found for EMG biofeedback plus thermal 
biofeedback (.075-2.14) indicates that there is more variability in this summary effect size 
than in some of the others. Close examination of the findings for EMG biofeedback plus 
thermal biofeedback indicates that the three primary effect sizes that make up the overall 
summary effect size are similar to each other and to the summary effect size (ln (OR)= 
1.10, 1.06, and 1.16; REM summary effect size In (OR) = 1.11) . Thus, the variation 
between studies is quite low. However, the confidence interval calculated using the 
random effects model takes into account within study variation as well as between study 
variation. Thus, this large confidence interval was likely effected by the within study 
variance. Of particular note is the within study variance found for Largen et al. (1981), 
the standard deviation of within study variance for this study was 1.21, the two other 
effect sizes for EMG biofeedback plus thermal biofeedback had standard deviations at .80 
and .85. Indicating that the Largen study introduced much of the within study variability 
found in this summary effect size. 
The high level of variability in Largen et al. ( 1981) may be explained by the 
sample sizes or the small effects that were reported. The Largen study has particularly 
small sample sizes ( experimental group N = 6, control group N = 5); small sample sizes 
can introduce more variability into the ln (OR) effect size calculations than larger sample 
sizes. In addition, the Largen study had only three successes in the experimental group 
(three of six), indicating that the odds of success in this condition were not greatly in favor 
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ofEMG biofeedback plus thermal biofeedback. These two added sources of variation 
may have widened the ln(OR) effect size confidence interval and may explain this finding 
in the current meta-analysis. 
The summary effect size in for EMG biofeedback plus thermal biofeedback (In 
(OR)= 1.11) is also low. The poor outcome for this type of treatment may have been 
influenced by several major factors; number of studies used to calculate the treatment 
effect, study characteristic, or a lack of a true treatment effect. Each of these possibilities 
is explored below. 
The summary statistic for EMG biofeedback plus thermal biofeedback is based on 
a small number of studies (N = 3). However, EMG biofeedback plus relaxation is based on 
only two studies, and the resulting summary statistic does not display a problematic 
confidence interval. Second, the poor outcome for EMG biofeedback plus thermal 
biofeedback may represent a study design flaw that negatively impacts the treatment 
outcome. An analysis of the studies used to find the summary statistic for EMG 
biofeedback plus thermal biofeedback shows that all three studies used control groups 
instead of wait list groups. It is possible, given difficulty finding appropriate attention 
placebo groups, that these control groups were flawed and systematically bias the 
outcome of this analysis. 
Examination of the individual studies indicates that one study used thermal 
biofeedback with temperature cooling as a control and the other two used groups that 
were told to relax daily. Both could bias findings by providing a treatment effect in the 
control groups. Temperature cooling has a mixed history of effectiveness. Several authors 
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(Blanchard et al., 1997; Gauthier, Bois, Allaire, & Drolet, 1981) have reported that 
temperature cooling biofeedback can be equally effective to thermal warming biofeedback. 
However , it is a commonly held belief that thermal biofeedback with a focus on 
temperature cooling is counter intuitive to migraine pathophysiology and is ineffective 
(Largen et al., 1981). The other two primary studies used to establish the effect size for 
EMG biofeedback plus thermal biofeedback had control groups that were "self-relax" 
groups. The self-relax groups were instructed to "relax" 10-15 minutes a day. There is a 
known treatment effect for structured daily relaxation technique. While these studies did 
not use structured techniques , the self relaxation instructions given to subject s may have 
resulted in a small treatment effect for the control group. Given that all three of the 
control groups have at one time been considered an active treatment on migraine 
headache , the "control" group participants in these studies may have benefitted to some 
degree from the instructions they were given, thereby reducing the difference between the 
two groups and decreasing the resulting OR. Anecdotal review of the studies used to 
calculate the summary effect size for EMG biofeedback plus thermal biofeedback lends 
support to this hypothesis. Each study in the EMG biofeedback plus thermal biofeedback 
treatment group reported that 20-30% of participants in control groups reached the 
success criteria (50% reduction in frequency of headache). This can be compared to the 
studies used in the EMG biofeedback plus relaxation treatment group who each report 
between 16-18% of participants in the control groups met the success criteria. 
Finally, the low effect size found for EMG biofeedback plus thermal biofeedback 
may reflect a true treatment effect. The three studies that utilized EMG biofeedback plus 
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thermal biofeedback all included initial sessions ofEMG biofeedback that were followed 
by thermal biofeedback training. It is possible that the initial EMG biofeedback training in 
some way interfered with the typically good outcome of the thermal biofeedback 
treatment. 
EMG Biofeedback plus Relaxation Techniques 
The ln (OR) summary statistic for EMG plus relaxation techniques is 2.47. This is 
the highest binary summary statistic found in the current meta-analysis. This summary 
statistic also has a large confidence interval (.93 - 4.0) The summary statistic is based on 
only two studies, they both resulted in high ORs but are somewhat different from each 
other (primary study ln (OR) = 2.11 and 3.86) , which would account for the confidence 
interval. The high level of treatment effect noted for EMG biofeedback plus relaxation 
training may have been influenced by the fact that both studies have relatively early 
publication dates (1979 and 1983), both included mixed headache patients, and both had 
very low quality ratings. In addition, one of the studies (Daly et al., 1983) was not 
randomized, the subjects were assigned to groups based on the severity of their symptoms. 
These study characteristics may have introduced bias that inflated the EMG biofeedback 
plus relaxation treatment effect size. 
Summary of Outcomes 
The findings of this meta-analysis indicate that five of the treatments evaluated 
produce moderate to large effect sizes. The one exception to this finding is the relatively 
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large effect size for EMG biofeedback plus thermal biofeedback. However, it is likely that 
the findings for EMG biofeedback were unduly influenced by study characteristics. This 
study's findings regarding effect sizes for these five treatments for migraine are nearly 
identical to those found by the Duke University study conducted for the Department of 
Commerce (Duke University and Center for Clinical Health Policy Research, 1999a, 
1999b). These studies reflect the same :findings although some of the statistical and 
selection procedures varied. This "replication " of the Duke University study offers strong 
support for the finding that these treatments offer similar moderate-to-large rates of 
effectiveness. 
It is curious to find that five different treatments based on highly varied theories 
and approaches have approximately the same treatment effect for migraine prophylaxis. 
Results based on OR indicate that between 40-70% of the subjects in clinical trials reach 
clinical reduction of symptoms (i.e., 50% reduction in frequency or headache index) no 
matter what treatment they receive. These :findings beg the question, "Why do these 
treatments all have approximately the same effect when they are so different?" While there 
is no succinct answer to this question, there are important factors that may contribute to 
this finding. The first factor impacting the treatment effects may be compliance. Second , 
migraine, as currently defined, may represent a set of disorders, some of which are 
amenable to the types of treatments currently being used and others that are not being 
affected. 
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Compliance 
Compliance has long been an issue for all long term treatments. Mullemers, 
Whitmarsh, and Steiner (1998) indicated that compliance in migraine prophylaxis is a 
major issue. They report that through the use of a computer monitoring system (secretly 
inserted into the lids of patient pill bottles) they were able to identify the actual compliance 
of subjects receiving migraine prophylactic treatment. Mulleners et al. (1998) reported that 
the used-on-schedule compliance rate (even in a controlled study) was, on average, 30% 
for participants who were to take medication two or three times a day 
(N = 18). Participants who took medications once a day averaged 66% used on schedule 
compliance rates (N = 11 ). The authors suggested that these low compliance rates 
significantly altered the effect of medical treatments intended to reduce the frequency of 
migraine. It is theoretically possible to extend these results to the nonpharmacological 
treatments for migraine. If patients have difficulty accurately taking a medication one to 
three times a day, it is questionable if they will adequately practice biofeedback techniques 
or relaxation techniques at 10-15 minutes per day. 
Mulleners et al. ( 1998) also found that patients were remarkably inaccurate about 
reporting to researchers how many pills they took. Even with a known compliance check 
(counting remaining pills) they found that there was a large difference between the amount 
of pills actually taken and the amount of pills reported to be taken. This :finding seriously 
calls into question the results of studies reporting nearly perfect compliance with treatment 
regunes. 
If compliance rates are as low as suggested by Mulleners et al. ( 1998), then it may 
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account for why none of these varied and sometimes intensive treatments have reached a 
desired level of effect or been able to differentiate one treatment from another. In addition, 
these :findings have "real world" implications for how usable daily treatments are for the 
general population. If subjects cannot partake of treatment in a prescribed manner during a 
highly controlled and structured situation, it is not very likely that they will appropriately 
engage in treatment under everyday living situations. 
Migraines as a Broad Category 
The current meta-analysis finds that treatments ranging from structured guided 
relaxation to calcium channel blockers have similar effects in migraine prophylaxis. It is 
possible that the finding of equivalent treatments effects indicates that more than one 
disorder is being treated by the migraine prophylactic treatments. Thus , chronic migraine 
headaches may be indicative of several different physiological and psychological pathways. 
If different disorders are currently grouped into the "migraine" category, and each 
treatment addresses a different underlying condition, it could account for the :findings of 
similar effect sizes. 
Recent genetic research may offer some support of this hypothesis. Although 
identifying genetic markers for diseases is still in its infancy as a science, some interesting 
:findings regarding migraine headaches have already been reported. For example, Goadsby 
( 1997) reported that familial migraine has been linked (in some families) to chromosome 
19pl3. Goadsby went on to report that preliminary :findings suggest that different families 
may be linked to other chromosomal regions. Of particular interest has been the finding 
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that for those who have a link to chromosome l 9p 13 some also have links to lower 
channel genes that are voltage-gated ionophores for Na+ and or K+. Flunarizine and 
Divalproex Sodium both have Na+ and Ca+ ion effects. Thus, these treatment may only 
work for those who have the particular genetic profile that is associated with Na+ deficits. 
As the area of genetic research broadens it may identify other familial deficits that best 
account for treatment effects of these and other types of treatments. 
While different types of migraines may exist , it appears that migraines are likely to 
all share common physiological pathways. If they did not , the current treatments would be 
unlikely to treat the noted large numbers. Goatsby ( 1997) reviewed experimental human 
and animal research and identified the common pathways that pharmacological agents 
share. Most prominent were the 5HT receptors and the calcium or sodium channels . 
Goatsby reported that most prophylactic pharmacological agents impacted at least one of 
the seven subclasses of 5HT receptors. Goatsby reported that Methysergide , Pizotifen, 
Propranolol, Amitryptiyline, Imipramine, and Flunarizine had documented effects on the 
5HT system. Alternatively, Goatsby noted that Flunarizine and Divalproex Sodium had 
documented effects on the active sodium and calcium ion channels . 
Nonpharmacological treatments have less experimental data available in the 
research. However, several authors hypothesize that nonpharmacological treatments 
promote biological homeostasis that reduces the likelihood that the above mentioned 
systems will be negatively impacted ( e.g., Blanchard et al., 1978; Feurstein, Bortolussi, 
Houle, & Labbe, 1983). Holroyd (2002) reported that cortical excitability has been 
strongly linked to the onset of migraine. Thie; excitability (related to neurogenic 
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inflamation that sensitizes nerve endings) can be altered through psychophysiological 
interventions that seek to quiet the system and thereby reduce brain stem activity 
(Holroyd). The brain stem has been implicated as the "migraine generator" due to its role 
in pain reception and vascular control (Weillner et al., 1995). Holroyd suggests that 
nonpharmacological treatments may be nonspecifically reducing the reactivity of the brain 
stem, making this a likely choice for the common pathway mechanism that the 
nonpharmacological treatments share. 
Goatsby (1997) focused mostly on pharmacological treatments; however, his 
comments on available research can be applied to both areas (pharmacological and 
nonpharmacological treatments) . 
The understanding of the action of preventative drugs is at a relatively immature 
stage. Recent developments in pharmacology and studies of pathophysiology of 
migraine have provided a substrate around which concepts can be developed. The 
actions and indeed the locus of action of the preventatives is crucial since these 
drugs are likely to point io the basic defect which underlies the process responsible 
for a migraine attack. (p. 90) 
Thus, suggesting that the common pathways that the pharmacological treatments share is 
a crucial yet undeveloped area of understanding. This statement can be applied to the 
understanding of the common pathways of nonpharmacological treatments, that are also in 
their infancy. Future research on how migraine prophylactic treatments work can help 
develop clearer understanding of migraine pathogenesis and would help to clarify why the 
treatments in the current meta-analysis have nearly identical effects . 
Sample Characteristics That Are Significantly 
Correlated with Outcomes 
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The current meta-analysis found that only two treatment groups displayed sample 
characteristics that significantly correlated with outcome. Study design significantly 
correlated with outcome for Propranonol and treatment length significantly correlated 
with outcome for Flunarizine. No other significant :findings for study characteristics were 
found. Notably , study quality was not among those sample characteristics that correlated 
with outcome . Below, significant :findings for Propranonol and Flunarizine are discussed , 
followed by a discussion of study quality. 
Propranonol and Study Design 
The regression analysis for Propranonol treatment outcomes for migraine 
prophylaxis identified that effect size outcome was significantly corr elated with study 
design. The finding indicated that cross-over designs produced higher effect sizes than 
parallel designs. This finding may be largely due to the method of including cross-over 
studies in this meta-analysis . The lengthy history of Propranonol as a migraine 
prophylactic has resulted in years ofresearch examining Propranonol's effects versus other 
pharmacological agents. This has resulted in a high number of primary articles that have 
cross-over designs. As previously mentioned, the results from cross-over designs have 
typically been ignored in meta-analyses. The current meta-analysis attempted to include 
the results by using a correlation in the calculation of effect size. When a correlation is 
included in the calculation of effect size the result is always of greater magnitude than 
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uncorrelated effect size correlations. Thus, it is not surprising to find that the two types of 
study designs produced systematically different outcomes. 
However, researchers have suggested that it is appropriate for cross-over designs 
to yield more powerful results than parallel designs (Kunkel, 1987). Cross-over designs 
are considered to hold at least twice the power of parallel designs because participants 
serve as their own control and their own comparison. The current meta-analysis chose a 
conservative approach to this issue. Correlations were gathered from all studies providing 
them and correlations were calculated for all studies that provided individual data. The 
lowest correlation obtained was substituted for all cross-over studies ( even if the original 
study provided a higher correlation). Thus, the finding that cross-over studies have higher 
effect sizes may be a product of the statistical procedures used in this analysis. The 
example of effect sizes for cross-over studies were calculated in Appendix F. It is clear in 
the example that the effect size is larger when the correlation is added in. Thus, the 
finding that cross-over designs had higher effect sizes is not surprising given that a priori 
decision to add more ''weight" to these studies by using correlations with all effect size 
calculations for cross-over designs. 
Flunarizine and Treatment Length 
The current meta-analysis found that effect sizes increased as length of treatment 
increased for subjects who were treated with Flunarizine. This is not surprising given that 
Flunarizine makes plasma levels increase slowly with daily oral administration. Serum 
levels do not reach a steady state for 4 to 6 weeks (Todd & Benfield, 1989). This indicates 
' 
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that it takes a longer time to reach a ''therapeutic dose" level in the patient . The slow 
effect ofFlunarizine is supported by the current outcome findings. Many of the original 
research articles on Flunarizine attempted to use the Propranonol research protocol that 
often treated patients for 8 to 12 weeks . Flunarizine's full effect seems only to begin to 
appear between 8 and 12 weeks. Thus, later research shifted to a 16- to 20-week protocol , 
with positive results . This appears to account for the finding that Flunarizine' s effect size 
seem to grow with length of treatment. 
Quality of Study 
The current study did not identify any statistically significant relationships between 
quality of study (as measured in this analysis) and outcome. The lack of association 
between quality of study rating and outcome is likely due to the selection criteria used in 
this meta-analysis. That is, the selection criteria were fairly rigid and may have selected a 
fairly homogenous group of articles. There were two quality rating scores obtained for 
each article included in the meta-analysis. The first was the Jadad Quality Score and the 
second was an author -developed study quality rating score. Quality of study in the current 
meta-analysis was defined in two ways: (a) quality of study as defined by Jadad et al. 
(1996) is defined as how much the authors report the use of high quality study design 
procedures (i.e., random assignment, double blinding, and description of dropouts), and 
(b) quality of study is defined by how well the authors addressed concerns related to 
migraine prophylactic treatment. The scale used to assess the first component of study 
quality was proposed by Jadad et al. and has been shown to have good inter-rater 
reliability and has been empirically validated as an assessment tool for study quality. The 
authors report that the instrument has been shown to be used consistently by raters 
regardless of background or training, indicating that it is likely to be valid and reliable in 
multiple settings including the current one. 
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The second quality score has a high inter-rater reliablity (reliablility coefficient was 
found to be .88). However, it has not been empirically validated. The quality score has 
face validity as it is based on the recommendations of the authors who were reviewed 
earlier. There it was identified that migraine prophylaxis treatment outcomes were often 
impacted by the following: type of measurement used (Holroyd & Penzien, 1990), type of 
control used (Compas et al., 1998), study design (Holroyd et al., 1991), use of run-in/ 
washout periods (Bogaards & ter Kuile, 1994) , multiple setting measurement (Bogaards 
& ter Kuile) , use of a comparison to another active treatment (Chambless & Hollon , 
1998), controlling other medication (Onghena & Van Houdenhove , 1992), and measuring 
compliance or home practice (Holroyd & Penzien). 
Each of the above variables were believed to pose threats to validity of reported 
outcomes in a study on the quality of a migraine prophylaxis outcome. However, the way 
these variable were rated ( as dichotomous, either present or not) and summed ( with some 
variables being seen as necessary and other being seen as important) has not been 
validated. The two quality of study ratings did reach similar results (no correlation 
between outcome and study quality) which may indicate that they both are measuring the 
same broad construct of study quality. Nevertheless, the only conclusion about quality of 
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study that can be drawn from the current meta-analysis is that quality of study as measured 
in this meta-analysis did not significantly correlate with treatment outcome. 
It should be noted that there were differences between treatments in the mean 
quality rating score . The following mean quality scores were obtained for each treatment 
(Jadad Quality Rating Scores are listed first, then study quality rating scores) , Propranonol 
(3.22, 2.48) , Flunarizine (2.83, 2.50) , Divalproic Sodium (2.57 , 2.14 ), thermal 
biofeedback (1.66 , 2.66) , relaxation treatments (1.83 , 2.81) EMG (1.45, 2.62) and thermal 
biofeedback plus cognitive therapy (1. 75, 2.50 ). 
The Jadad Quality Score ranges from O -5. These scores indicate to what degree 
the researchers used appropriate research design to rule out threats to validity. The scale 
rates each article on the following: random assignment (up to 2 points) , double-blind 
design (up to 2 points) and description of drop outs (1 point). Average scores above 3 on 
this scale are likely to indicate studies of high quality that have relatively few validity 
threats as a result of study design. The only treatment that exceeded an average Jadad 
score of 3.0 was Propranonol (3.22). An average score between 2 and 3 represents a 
group of studies that may have more significant threats to validity as a result of study 
design or may have had inadequate published reporting of the study design. Both 
Flunarizine (2.83) and Divalproic Sodium (2.57) fall into this category. A score below 2 
on the Jadad Quality Scale indicates a group of articles whose findings may have serious 
threats to validity due to study design. All the nonpharmacological studies fall into this 
category, this is due to the lack of"'double blinding." None of the behavioral articles 
received credit for double blinding, reducing the scores of all behavioral studies by at least 
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2 points. Double blinding is a proposed research technique that is designed to reduce the 
effect of experimenter/participant expectation on outcome. The ability to actually achieve 
true double blinding is questionable. It has been argued (e.g., Kirk-Smith & Stretch, 2001; 
Turner, Jensen, Warms, & Cardenas, 2002) that treatment providers (nurses, doctors, 
etc.) and participants in pharmacological treatment evaluation studies with double-blind 
conditions are able to guess which treatment condition they are in ( experimental or 
placebo). Thus, potentially invalidating attempts to double blind the study. Double-
blinding becomes even more problematic when nonpharmacological treatments are 
considered. Some authors ( e.g., Lukoff, Edwards, & Miller, 1998) have argued it is nearly 
impossible to double blind a nonmedical intervention that involves providing an office-
based intervention. Whether possible or not the attempts at double blinding in the field of 
psychological and behavioral research appear to be very low. Sheldrake (1998) reported 
that in a review of the top psychological journal only 9% of experimental articles use a 
double-blind methodology. This low use of the double-blind methodology is reflected in 
the nonpharmacological study of migraine prophylaxis. The nonpharmacological treatment 
results must be interpreted with caution due to the limited use of double blinding. 
The second type of quality rating used in this meta-analysis was developed by the 
current researcher and was based on previous literature reviews on migraine prophylactic 
treatments. The Jadad Quality Rating scale focuses on characteristics of standard study 
design, the second quality rating focused on variables that spedifically pose validity threats 
in headache outcome studies. For example, did the researchers include a wash-out period 
in which participants were withdrawn from other medications so that the experimental 
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treatment alone could account for treatment effect? This quality rating score ranges from 1 
to 3, with 3 representing the highest quality score. The quality ratings for the treatments 
examined were fairly consistent across treatment type. The mean scores ranged from 2.14 
to 2.8, indicating that the articles included in this meta-analysis fairly consistently 
attempted to control for variables that are known to impact treatment outcome in migraine 
prophylaxis. 
Do Outcomes Vary if Broken into Two Levels 
of Empirical Evidence? 
Chambless and Hollon ( 1998) suggested that the "premiere" type of outcome 
research compared a treatment that was known to be effective to one that was being 
tested. They suggested that a treatment reported to be better than placebo revealed 
nothing about how it compared to other available treatments and thus was not as useful. 
The current meta-analysis attempted to identify whether this premiere type of research 
actually provided different information or just more convenient information. To address 
this issue placebo/control groups were coded separately from comparison group studies. 
This variable (along with other identified variables of interest) was entered into regression 
analysis for each treatment to identify if treatment outcome systematically varied by the 
type of comparison group ( control vs. active treatment). The findings of the present meta-
analysis indicated that none of the regression analyses included the variable '"treatment 
comparison group" as a significant variable related to outcome (see Appendices G, H, I, 
and J). Thus, in the area of migraine prophylaxis, the type of outcome information 
provided by comparison research studies was similar in magnitude to the information 
provided in placebo/controlled studies. 
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In the area of migraine prophylaxis treatment outcome identifying the premiere 
type of research may depend largely upon how the author reports the results. Migraine 
prophylactic treatments, as shown in the present meta-analysis, have very similar treatment 
outcomes. Thus, comparison studies do little to enlighten us about which treatment is 
better , rather they merely confirm that there is no statistical difference between treatments. 
If the author chooses to only report nonsigni:ficant results between two active treatments, 
then the results of comparison research studies cannot be synthesized with other research 
studies. Such reporting makes comparison research studies less "useable" than 
placebo /controlled studies. Thus , Chambless and Hollon's (1998) suggestion that 
comparison studies are the most valuable way to compare studies may only be true when 
there is comprehensive reporting ofresults. If this is not the case, articles that provide 
effect size information are equally useable regardless of whether a comparison group was 
used or not. 
Information Available Regarding Short-
and Long-Term Effectiveness 
The current meta-analysis coded for length of treatment and length of follow-up. 
Each treatment varied in the amount of long-term data that was collected. Overall, all six 
treatments showed that effects of treatment were maintained as long as treatment was 
maintained. Most treatments examined in the present meta-analysis have studies showing 
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up to 6 months of treatment with positive outcomes. However, examination of treatment 
effects after discontinuation of treatment is difficult to determine. The methodological 
problems of determining long-term effects for a previous treatment for migraine will be 
discussed below. Followed by a discussion of known long-term effects of treatments 
evaluated in the present meta-analysis. 
Methodological Problems 
Data on migraine prophylactic treatments after the treatment has been discontinued 
are valuable . However , studies that attempt to follow up on a migraine prophylactic 
treatment face some inherent problems. First, it is unethical to maintain control groups for 
long periods of time when known treatments exist. Second , without a control group it is 
impossible to tell if the reported levels of symptomology are related to the previous 
treatment or the waxing and waning nature of migraine. Wnen long periods of time are 
involved it is nearly impossible to rule out alternative explanations for reductions of 
reported symptoms from baseline. Finally, the selection process in follow-up studies is 
flawed due to unavoidable selection bias. Each of these issues are addressed below. 
The issues related to the lack of control groups for long-term outcomes is a 
significant one. First, it is considered unethical to withhold treatment from a control group 
once the active phase of the treatment has been discontinued (Sorbi, Tellegen, & DuLong, 
1989). Therefore, many researchers offer the active treatment to control subjects after the 
first phase of the study discontinues. Once the subjects have been treated, there exists no 
treatment-free group with which to compare the results of patients after a certain amount 
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of time has elapsed. The absence of a control group precludes the calculation of an effect 
size for inclusion in a meta-analysis. 
Second, the absence of a control group in a long-term prophylactic treatment 
outcome study for migraines is particularly problematic due to the nature of migraine 
headaches. Migraine is considered to be a cyclical condition in which cycles of migraines 
occur and remit in an unpredictable fashion (Couch, 1987). Symptoms of migraines are 
highly variable and can include intense periods of :frequent migraines and extended periods 
without migraines. Couch reported that between 28-60% of migraine sufferers have 
symptoms that remit with placebo treatment. Thus, when long-term studies report that 
treatment gains are maintained or improved at three years, it is difficult to determine if the 
effects are actually related to the initial treatment , or, if, in the normal course of migraine, 
the symptoms have simply remitted. 
A third related issue is the possibility of alternative explanations for treatment 
effects that are not due to the course of migraine itself It is impossible to control for all 
historical, maturational, and alternative treatment effects over an extended follow-up 
period. The possibilities for alternative explanations are nearly endless. A subject may have 
moved, tried an alternative treatment, married, changed jobs, had children, or had children 
leave the home. When these issues are not controlled via randomization and controlled 
comparison groups it is difficult to connect the level of symptomology to a previous 
treatment. 
Finally, selection bias becomes an issue in follow-up studies. Researchers generally 
only include results of those subjects that can be contacted. It is rare that all subjects who 
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participated in the initial research study can be contacted. Thus, it is possible that those 
who are available are significantly different than those who are not. In addition, many 
researchers complicate the issue of selection bias at follow-up by attempting to contact 
only those who had a positive outcome to the initial treatment. While intuitively appealing, 
this procedure selects for not only those who had positive effects, but also for those who 
can still be reached. This does little to provide information about the true long-term 
prophylactic effect of a treatment. 
These issues suggest that the determination oflong -term effects after treatment for 
migraine prophylaxis is difficult at the best . Fortunately some long-term treatment 
information is available for up to 5 years on some migraine prophylactic treatments and 
this information is reviewed below by treatment category. 
Propranonol Long-Term Effects 
Primary articles included in the present meta-analysis for Propranonol had 
treatment lengths that ranged from 4-52 weeks. This is the amount of time that the 
participants were taking Propranonol. Effect size did not significantly correlate with length 
of treatment (r = -.272), indicating that participants achieved essentially the same 
reduction in symptoms whether they took Propranonol for 1 month or 12 months . The 
following authors reported that Propranonol effects were clearly maintained for up to 1 
month after discontinuing the medication: Daholf (1987), Kangasniemi et al. (1983), 
Nadelmann et al. (1986) , and Rao et al. (2000). Rao et al. reported that "successful 
treatment" effects are maintained for at least 5 months after discontinuation of daily 
treatment with Propranonol. 
Flunarizine Long-Term Effects 
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Primary articles included in the present meta-analysis for Flunarizine indicate that 
there is a long-term treatment effect. As previously discussed, Flunarizine shows greater 
effect sizes the longer it is taken . Studies included ranged in treatment length from 4-24 
weeks. Regression analyses indicated that effect sizes were significantly larger when 
treatment length was longer (R2 = 5.37, F =I5.06) . Only one study included in this meta-
analysis reported follow-up data on migraine relief after discontinuation of treatment with 
Flunarizine. Nuti et al. (1996) indicated that follow-up data showed that positive results 
were maintained for 8.4 months± 4.0. 
Divalproex Sodium Long-Term Effects 
Primary articles included in the present meta-analysis for Divalproex Sodium 
indicate that effect size does not vary with active treatment length. Treatment length did 
not significantly correlate with effect size (r = -.223). Treatment lengths varied in the 
present meta-analysis from 6-24 weeks. None of the articles included in the present meta-
analysis provided information on maintenance of effect after discontinuation of active 
treatment with Divalproex Sodium. Ghose and Niven (1998), in an article that was 
disqualified from the present meta-analysis, reported that 60% of subjects maintain gains 
for up 24 months with daily medication. In addition , Rothrock and Mendizable (2000), 
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also not included in the present meta-analysis, reported that 60% of patients indicated that 
gains made on Divalproex Sodium were maintained up to 2 months . 
Nonpharmacological Long-Term Effects 
Thermal biofeedback , relaxation treatments, and combination treatment outcome 
studies show a different trend than pharmacological treatment studies. The 
nonpharmacological treatments appear to focus on the effects of making treatments 
shorter rather than longer. Thermal biofeedback and EMG biofeedback have both 
experimented with brief therapeutic contacts that utilized at-home practice. The magnitude 
of the treatment effect sizes do not statistically significantly change under these conditions . 
For example, Blanchard et al. (1985b) reported that outcomes did not statistically 
significantly differ whether they used brief biofeedback/relaxation training (2.6 hours of 
therapeutic contact) or traditional training (11.6 hours of therapeutic contact) . 
Articles that were included in the present meta-analysis on thermal biofeedback 
ranged from 5-32 therapeutic contacts. Relaxation treatments range from 5-12 therapeutic 
contacts. EMG biofeedback ranged from 5-12 therapeutic contacts. Relaxation treatments 
and thermal biofeedback plus cognitive therapy ranged from 5-37 weeks and between 4-16 
therapeutic contacts. Effect sizes did not vary by treatment length for thermal biofeedback 
(r = .159) or relaxation therapy (r = .459). Some authors do address how longer term 
active treatment affects treatment outcomes. Andrasik, Blanchard, Neff, and Rodichok 
(1984) reported that up to 80% of subjects trained to use progressive muscle relaxation or 
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progressive muscle relaxation, and thermal biofeedback maintained significant treatment 
gains at 1 year when given monthly contacts for retraining. 
Several reports regarding posttreatment outcomes are available. Many authors 
report that the effects of thermal biofeedback, relaxation treatments, and EMO treatments 
are effective for at least 4 weeks after discontinuation of treatment (e.g., Blanchard, 
Andrisak , Neff, Arena, et al., 1982; Holroyd et al., 1995; Holroyd et al., 1988; Jurish et 
al., 1983). Some have reported even longer term gains, Blanchard, Appelbaum, Nicholson 
et al. (1990) rep011ed a 4-month maintenance of treatment gains for thermal biofeedback 
treatment when the participant achieved an initial 50% reduction in frequency during initial 
treatment. Daly et al. (1983) reported that participants who were given thermal 
biofeedback or EMG biofeedback maintained gains for up to three months but that those 
given relaxation training did not. A six year follow up conducted by Lispers and Ost 
( 1990) indicates that treatment effects are largely maintained for up to 6 years for 
participants treated with biofeedback (EMG or thermal). Similarly, Sorbi et al. (1989) 
reported that participants who could be followed for 3 years maintained or increased 
frequency reductions of migraine when they received relaxation training. Richardson and 
McGrath (1989) reported positive 6-month outcome effects for participants who received 
thermal biofeedback and cognitive therapy. They reported that mean treatment frequency 
scores were statistically significantly lower than baseline at a 6-month follow-up. 
However, Blanchard et al. (1978) reported that by 4 years those treated with thermal 
biofeedback or relaxation training were approaching baseline frequencies of migraine 
headaches. 
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Summary 
The effects of Jong-term treatment for migraine can be summarized as follows. 
Once a reduction of symptoms is achieved via any of the above treatments an individual is 
likely to maintain that reduction of symptoms as long as they are actively being treated. 
Once the treatment is discontinued the effect may vary by treatment . Propranonol effects 
may maintain for at least a month, Flunarizine effects may maintain for 8 months , 
Divalproex Sodium may maintain for up to 2 months, thermal biofeedback and EMG 
biofeedback may maintain for 6 years , relaxation treatments may maintain for up to 3 
years, and thermal biofeedback plus cognitive treatments may maintain for 6 months . 
However, all of these results should be interpreted with caution due to methodological 
pro bl ems inherent in the studies. 
Practical Implications 
The findings of the present meta-analysis do little to clarify which treatment should 
be recommended. The results indicate that most of the treatments reviewed produce nearly 
the same effect size. All effects (excluding those from EMG biofeedback treatments) are 
considered moderate to large. Thus, individuals who choose from among Propranonol, 
Flunarizine, Divalproex Sodium, thermal biofeedback, relaxation therapy, and thermal 
biofeedback plus cognitive therapy for migraine prophylaxis are likely to see some 
reduction of symptoms. 
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As a result determining the treatment of choice must take into account factors 
other than effectiveness rates . Ward (2000) suggested that the selection of treatment for 
migraine prophylaxis should be made on the basis of comorbid disorders . If another 
condition exists that can simultaneously be treated with one of the agents, then this 
treatment should be selected first . Ward reported that some commonly found conditions 
(and treating agents) that should be considered are hypertension (Propranonol) , mitral 
valve prolapse (Propranonol) , anxiety (Propranonol) , bipolar disorder (Divalpoex 
Sodium) , epilepsy (Divalproex Sodium), Raynauds disease (Flunarizine ). An excellent 
decision tree that considers comorbid disorders and contraindications for migraine 
prophylaxis pharmacological treatment appears in Adelman and Von Seggem (1995). 
Ward (2000) did not mention the use of nonpharmacological treatments but the 
same logic applies. Previous research shows that these nonpharmacological treatments 
work well for conditions other than migraine prophylaxis. Researchers have documented 
that thermal biofeedback and relaxation therapy are effective in treating anxiety 
(Culpepper, 2002), depression (Setter & Kupper, 2002), and high blood pressure (Setter 
& Kupper). Thermal biofeedback in particular has been noted to treat circulation issues in 
Raynauds disease (Sappington & Fiorito, 1985 ) . As can be seen, Ward's suggestion to 
select via comorbid disorders narrowed the fields of treatments, but did not identify a 
single best choice treatment. 
Another consideration in choosing a treatment may be compliance. As previously 
mentioned compliance with treatment regimes is a documented problem in migraine 
prophylaxis (Mullemers et al., 1998). The above-researched techniques will not have the 
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complete desired effect if the individual is unable to comply with treatment 
recommendations. If compliance issues are of concern for an individual, then issues that 
impact compliance should be considered when selecting the treatment of choice. One way 
of selecting the best treatment may be choosing the one that requires the least time and 
energy expenditure. Of the above treatments, Propranonol and Flunarizine are likely to be 
adhered to with the least amount of problems (each treatment can be administered on a 
once-a-day schedule). Given that Flunarizine is not available in the United States , 
Propranonol would be the treatment of choice. Divalproex Sodium requires greater 
compliance because it may be administered up to three times a day and requires regular 
laboratory exams for safety reasons. All nonpharmacological treatments require more time 
investment from the treated individual. However, an advantage to using 
nonpharmacological treatment is the ability of the clinician to monitor compliance. That is, 
many treatments involve components with the individual participating in their treatment in 
the presence of the clinician. 
When selecting the treatment of choice patient preference cannot be ignored. The 
side effects profiles, time commitments, and long-term effects vary widely between these 
treatments. Individuals often have specific belief systems that influence their preferences 
for treatment. Individuals needing migraine prophylactic treatment should be informed of 
the options and included in the decision making about treatment of choice so they can be 
active participants in their own health care (Capobianco et al., 1996). Individuals who are 
involved in making their own treatment decisions are more likely to value the treatment 
they have chosen and, thus, adhere better to treatment guidelines. 
106 
Finally, cost considerations need to be addressed. Adehnan and Von Seggern 
(1995) identified that Propranonol (the twice-a-day preparation) as the least expensive 
treatment. However, the one-time-a-day preparation was almost four times as expensive. 
Divalpoex Sodium weighed in at almost 12 times the cost of the twice-a-day Propranonol. 
Estimates for Flunarizine are not available given that it is not legal to sell within the United 
States. The above estimates include only medication costs. The cost of doctor visits, 
laboratory work , and third-party fees are not estimated. So this is an estimate of only a 
part of the costs associated with the pharmacological treatments. Osterhaus and 
Townsend ( 1991) estimated at that time that other medical costs per year per patient for 
migraine management included $281 for emergency room visits , $148 for clinic visits, and 
$387 for hospitalizations, averaging an additional $68 a month for pharmacological 
treatments. 
Nonpharmacological treatments are initially expensive. Treatment per session 
prices can average $80. If seen weekly, the cost per month could be $240 , where 
Divalproex Sodium plus monthly medical expenses are estimated at $158 per month. 
Attanasio, Andrasik, and Blanchard (1987) reported that there was little difference in the 
cost effectiveness between nonpharmacological treatments. All nonpharmacological 
treatments have similar costs associated with the initial training. Importantly , Blanchard, 
Jaccard, Andrasik , Guarnieri, & Jurish (1985) report that nonpharmacological treatments 
significantly reduced costs after termination of treatment due to long-term effects and 
patient self-management. As previously mentioned, long-term studies evaluating the 
effects of nonpharmacological treatment effects indicated that reduced frequency of 
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migraine is maintained up to 6 years (Lisspers & Ost, 1990). Pharmacological treatments 
have very little support as to having a lasting treatment effect beyond a few months after 
the active treatment phase. This suggests the costs associated with nonpharmacological 
treatments are one-time costs where pharmacological costs are ongoing. Blanchard, 
Jaccard, et al. (1985) reported that medical costs associated with treating headaches were 
approximately $1,000 per year prior to nonpharmacological treatment and approximately 
$50 per year following treatment ( costs include medical costs and lost productivity). The 
long term effects after treatment is discontinued indicate that nonpharmacological 
treatments may be more cost effective than pharmacological treatments in the long nm. 
In sum, a variety of factors influence treatment choice for migraine prophylaxis. 
There is no single best choice for all individuals. Comorbid disorders , cost , and 
compliance are just a few of the considerations in making the choice. However , the 
current meta-analysis suggests that once the choice is made, if compliance is high, the 
treatment is more likely than placebo to reduce frequency of headaches. 
Limitations 
The current findings are limited in several ways. First, these findings are directly 
reliant on the quality and accuracy of the findings in the primary research. Second, the 
combination of these two major bodies of research has resulted in the mixing of some 
groups that may not be compatible. Finally, significant problems exist in the primary 
literature for nonpharmacological treatments that limit their findings. Each of these 
limitations are discussed below. 
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Quality of Primary Research 
These findings cannot outstretch the initial accuracy of the articles on which they 
are based. The current meta-analysis attempted to address this issue through the use of 
quality ratings. However, it should be noted that the quality scores used in this meta-
analysis only address a few factors that could compromise outcome validity and reliability. 
Thus, other serious threats or flaws may exist in the primary research that would challenge 
the findings of this meta-analysis. The present meta-analysis supports the findings reported 
by other meta-analytic studies (Duke University and The Center for Clinical Health and 
Policy, 1999a, 1999b; Holroyd & Penzien; 1990). Nevertheless, all of these meta-analyses 
have been based on the same primary research literature and may be subject to the same 
primary flaws. 
Summing Data 
Subjecting the two bodies of research (pharmacological and nonpharmacological) 
to the same standards and coding methods revealed several differences between the two 
literature bases that may limit these findings. There are several procedural and 
nomenclature differences between the two groups that may cause the outcome findings to 
be limited. For example, the term ''vascular headache" is one commonly used in the 
behavioral research. This term is defined as some form of migraine (mixed, classic, or 
common). Researchers in the behavioral area often report results for the vascular headache 
subjects as a group. The pharmacological research does not typically use mixed groups. 
They tend to select subjects who have very specific migraine symptoms and then report 
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results in two migraine categories (common or classic). The research included in this 
meta-analysis for pharmacological treatments rarely included mixed headache patients. 
However, subjects with transformed headache ( a condition where individuals with 
migraine headaches begin to have daily tension headaches intermixed with migraines due 
to medication/reinforcement issues) are included in some pharmacological studies. 
Subjects with transformed headache are not addressed in the nonpharmacological 
research. This meta-analysis combines this diverse information into single summary effect 
sizes for migraine headache treatments. In the process of summing these two diverse 
bodies of literature some specific information may have been lost. Thus, the comparison of 
the outcome of the treatments is limited to broad generalizations. 
Problems in the Nonpharmacological Literature 
The :findings for nonpharmacological treatments are significantly limited by (a) the 
lack of studies that use an appropriate control or attention placebo group, and (b) an 
overreliance on the percent improved score. The paucity of published controlled studies 
on nonpharmacological treatments is not from the lack of trying. Rather, studies designed 
as controlled trials have often selected attention placebo conditions that later demonstrate 
an active effect. Researchers have attempted to use relaxation (Lacroix et al., 1983), 
pseudo-meditation (Blanchard, Appelbaum, Radnitz, et al.. 1990), hypnosis (Reich, 1989), 
false biofeedback (Reading, 1984), home biofeedback (Blanchard et al., l 985a), and 
contact with a therapist by phone (Richardson & McGraph, 1989) as attention placebos. 
However, each of these groups has shown similar effects to the active treatment group. 
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The only control groups that appeared to consistently not have big treatment gains were 
wait list groups. This phenomenon resulted in markedly fewer controlled studies that were 
available for systematic review for nonpharmacological treatment than for 
pharmacological treatments. 
The second limiting factor found in the existing literature on nonpharmacological 
treatments was the overreliance on the percent improved score. The percent improved 
score was the individual improvement scores average for the group of treated individuals. 
For example, authors may report that those in the thermal biofeedback group had a 
percent improved score of 48%. Many authors in the nonpharmacological migraine 
treatment area report this score as their primary outcome index. When this is the case , 
individual data are lost because it is impossible to tell if the individuals in the treatment 
group went from 4 headaches a month to 2 headaches a month , or from 10 headaches a 
month to 5 headaches a month. Both are significant changes but have different meanings. 
In addition , it is not standard to report the percent improved score with variance scores. 
Therefore , it is impossible to tell if most subjects in the study were near the reported 
percent improved score or if there was a great deal of deviation. Without standard 
reporting of variance these scores become less meaningful. 
The combination of the lack of a true control condition and inadequate statistical 
reporting (primarily due to the overuse of the percent improved score) resulted in a large 
number of primary research articles that could not be quantitatively compared. These 
studies did not lend themselves to standardization via quantitative methods and thus had to 
be disqualified from the current meta-analysis. As a result, this meta-analysis is based on 
111 
only a :fraction of primary articles available on nonpharmacological treatments. Therefore, 
the conclusions drawn from these findings may be limited by being based on only a small 
portion of the available research findings. 
Suggestions for Future Research 
Continued research in the area of migraine prophylaxis is recommended, however, 
prior to beginning new trials researchers need to recognize what is not needed in this area. 
Research on why biofeedback treatments are superior to relaxation treatments for 
migraine prophylaxis is no longer needed because the current body of literature shows that 
biofeedback is not superior to relaxation treatments. Though not directly addressed in this 
meta-analysis there is also no current need to establish the ideal body temperature change 
that a person needs to obtain for biofeedback to be effective. Results clearly ind.icate that 
classic and common migraine patients cannot change their body temperature as readily as 
other type of subjects; however, ability to reach certain temperature changes does not 
correlate with the decrease of headache frequency (Werbach & Sandweiss, 1978). 
Another course of action that no longer seems warranted is research on combination 
therapies that do not use two empirically validated treatments. There is not a valid 
rationale for throwing treatments together that have not been established as effective by 
themselves (e.g., EMG biofeedback plus hypnosis with autogenic training). Finally, the 
role of Propranolol is clearly established in migraine prophylaxis. There is little need for 
continued controlled trials to replicate this finding. 
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These areas aside, the findings of present meta-analysis indicate future research is 
needed in the area of migraine prophylaxis. More research is needed on (a) controlled 
trials on nonpharmacological treatments, (b) the effect of combining empirically supported 
treatments from the two categories (nonpharmacological and pharmacological) , and (c) 
the development of a comprehensive theory on migraine that combines findings from 
different fields. Each of these suggestions are discussed below. 
First, the value of nonpharmacological prophylactic treatments ( other than thermal 
biofeedback) needs to be clearly established. This can only be done through clearly 
controlled basic research studies that replicate outcome findings. The lack of basic 
research on commonly accepted techniques for nonpharmacological treatments is 
alarming. Many authors have shifted on to investigating correlates of outcomes for 
relaxation and cognitive techniques, citing as part of their study rational that the benefits 
of these treatments are clearly documented by other authors (e.g., Hart, 1984). This is not 
a valid rationale for all nonpharmacological treatments. As shown in the current meta-
analysis, there is a large body of research regarding the use of these techniques for 
migraine prophylaxis ; however, very little of the research works to establish that the basic 
effects of these treatments are greater than placebo/control group gains. 
A related issue is the need for the identification of an appropriate attention placebo 
condition for migraine prophylaxis. The definition of attention placebo as it relates to 
behavioral interventions has often been debated. Definitions for attention placebo as it 
applies to nonpharmacological treatments include: (a) a treatment or procedure that has no 
specific effect, but that can be presumed to have an effect (Shapiro & Morris , 1978), (b) a 
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substitute for a genuine treatment (Senger, 1987), and ( c) nonspecific treatment facters 
that encourage hope, learning, sharing, emotional arousal, and mastery, but do not provide 
any specific effect (Fish, 1973). The variety of definitions available for attention placebo 
stems large]y from the attempt to apply a medical term to psychotherapy. The term 
placebo in medical arena's refers to the procedure of giving an inactive substance in the 
place of a chemically active substance to rule out interpersonal and expectation factors as 
a cause of outcome (Senger). This, obviously, is a difficult concept to apply to 
nonpharmacological interventions that rely on interpersonal factors for treatment. This has 
led some authors to suggest that effects of psychological and behavioral treatments are 
nothing more than extensive placebo effects ( e.g., Patterson, 1967). Thus, it may be 
argued that the observed effects for nonpharmacological prophylactic treatments for 
migraine are merely attention placebo effects. A strong argument against this comes from 
Mathew ( 1981 ), who reported multi-arm treatment findings. He suggested that thermal 
biofeedback and Propranolol have similar effectiveness rates, but that both are better than 
placebo. If thermal biofeedback were just a strong placebo effect, one would expect the 
efficacy rates to be lower than Propranolol and more equivalent to placebo results. 
However, this is not the case . 
Thus, it is likely that thermal biofeedback, relaxation therapy, and combined 
therapies have a specific effect that causes the reduction of migraine frequency. If this is 
the case, this effect needs to be demonstrated above and beyond hope, expectation, and 
interpersonal factors through controlled studies that employ attention placebo groups. 
In the pharmacological migraine prophylaxis literature, the placebo effect has been 
demonstrated to account for at least 35% improvement in migraine frequency (Couch, 
1987). If this same approximate rate can be applied to nonpharmacological treatments, 
then an attention placebo could be defined as a treatment that does not include specific 
treatment factors that causes approximately 35% improvement but does not equal total 
treatment effect of the active treatment. The present study will use this definition of 
attention placebo. 
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The difference between attention placebo groups and active treatment groups 
needs to be established in the nonpharmacological literature. It is apparent in the existing 
body of literature on nonpharmacological migraine prophylaxis that any attention placebo 
condition that involves regular visits, sitting alone in a treatment room, machines that have 
face validity, or guided relaxation treatment at home , will show a treatment effect and, 
therefore, not be an attention placebo. This suggests that the nonpharmacological 
treatments have a common active component that has yet to be explained. It is possible 
that the act of routinely engaging in a quieting or calming activity or that the education 
provided when the treatments are undertaken, or that providing a rationale to participants 
may be the common active feature. Many authors have documented the fact that the 
nonpharmacological treatments are better than wait list controls ( e.g., Blanchard, 
Appelbaum, Nicholson, et al., 1990; Blanchard, Nicholson, Radnitz, et al., 1991; Gauthier, 
et al., 1985). It can then be assumed that the nonpharmacological treatments are 
providing treatment beyond time and daily self- monitoring, but how they are providing 
this treatment is still uncertain. An important part of discovering the active components in 
nonpharmacological treatment will be identifying an attention placebo that does not elicit 
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the same treatment effect. The studies included in the current meta-analysis in the EMG 
biofeedback plus thermal biofeedback plus relaxation treatment condition may offer some 
guidance in this area. This treatment category included three primary articles that used 
control groups that document approximately 20-30% gains. These gains are similar to 
those often reported for placebo (i.e., 35%). Two of the studies included control groups 
who were told to go home and relax without specific instruction (McGrady et al., 1994; 
Waquier et al., 1995) . The fact, that the authors were able to document treatment effects 
for EMG biofeedback plus thermal biofeedback plus relaxation above and beyond their 
control group is promising. It should be noted that the net result in the current meta-
analysis of using control conditions rather than a wait list group was a lower summary 
effect size for this treatment (In (OR) = 1.11) . This may suggest that when a true 
attention placebo for nonpharmacological migraine prophylactic treatment outcome 
studies is found, the noted treatment effect sizes for the nonpharmacological treatments 
may be reduced ( due to the methods of calculating effect sizes) 
It appears that adding treatments within a category (nonpharmacological or 
pharmacological) does little to improve the efficacy of the treatment. This is most clearly 
see in the nonpharmacological treatments. Results show that most treatments in the 
nonpharmacological area have the same effect even if they are combined (e.g., thermal 
biofeedback and thermal biofeedback plus relaxation plus cognitive therapy have nearly 
the same effect sizes). However, future research in the area of cross-category combination 
treatment is needed. Taking a treatment from the nonpharmacological category and one 
from the pharmacological category that are both empirically supported and combining 
116 
them is a relatively unexplored area . There are currently only two articles that examine the 
effects of one of these combinations; thermal biofeedback plus Propranonol (Holroyd et 
al., 1995; Mathew, 1981) Both studies reported promising results. Holroyd, France, et al. 
reported that the use of a combined thermal biofeedback and Propranonol approach was 
significantly better than using biofeedback alone. Mathew (1981) reported that thermal 
biofeedback plus Propranonol was superior to Propranonol alone, or thermal biofeedback 
alone . In addition, Mathew reported that biofeedback plus Propranonol was superior for 
migraine prophylaxis to all seven treatments examined in the same article ( control, 
Propranonol , Amitriptyline, thermal biofeedback , Propranonol plus Amitriptyline, 
Amitriptyline plus thermal biofeedback, and Propranonol plus Amitriptyline plus thermal 
biofeedback) . However , the author notes that these results are for migraine headache only 
and that results for mixed headache differ. It is interesting to note that both articles are 
relatively old by research standards and that little has been done to follow-up on their 
findings. 
A primary need in the area of migraine research is a new guiding theory that takes 
into account the available research findings. Much of the research on migraine prophylaxis 
appears haphazard and undirected. This may be due to the lack of a unifying theory about 
the course of migraines and bow variables interact with one another. There seems to be 
very little work being published that attempts to integrate findings on migraine from 
various research fields. Pharmacological, nonpharmacological, genetic, and biological 
researchers are reporting some perplexing findings that need to be addressed. For 
example, why do false biofeedback and true biofeedback not statistically significantly differ 
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in outcome for migraine prophylaxis when they both are statistically better than wait list 
groups? Or why does Propranonol seem to be one of the few beta-blockers that actually 
works as a migraine prophylactic? And why do Propranonol, thermal biofeedback, or 
practicing home relaxation seem to all have similar effect? 
The development of a theoretical hypothesis that synthesizes these and many other 
results could direct researchers toward potentially fruitful areas of research and away from 
repeated problems of the past. The unification of many fields through theory would allow 
researchers to work with each other. Potentially, a concrete theory could help eliminate 
the irrelevant and redundant research that is present in this body of literature (e.g., 30 
years of research that uses relaxation as a control group or repeated studies on the brand 
of machine needed to give biofeedback when a basic thermometer seems to work just as 
well). 
In sum, research on migraine and migraine prophylaxis needs to be theory driven. 
Ideally, the theory would address the pathogenesis, genetic research, psychological 
contributions, common pathways, and treatment of migraine. The theory would address 
the results of the present meta-analysis and the results of other meta-analytic studies that 
indicate treatments have similar effect sizes and none of these effect sizes are as high as 
one would hope after 30 years of research. In addition, the theory would suggest specific 
hypothesis that could be tested in various fields. Such a unifying theory seems crucial to 
reaching a better understanding of the complexity of migraine headaches. 
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Appendix A: Pharmacological Agents' Names 
Table Al 
Pharmacological Agents' Names 
Category Brand name Generic name Chemical nan1e 
Beta-adrenergic Inderal® Propranonol *(Isopropylanuno )-3-(1-n 
blocker aphthyloxy)-2-propanol 
hydrochloride. 
Calcium channel Sibelium ® Flunarizine * ( 4-fluorophenyl)-Methyl 
blocker -4-(3-phenyl-
2-propenyl) 
*piperazine-
dihydrochloride. 
Anti-convulsant Depakote ® Divalproex *sodium hydrogen 
Sodium (2-propylpentanoate ). 
*valproic acid 
* sodium valproate 
Table Bl 
Summary of Reviews 
Authors (date) 
Blanchard, Andrasik, 
Ahles, Teders, & 
O'Keefe (1980) 
Type of 
headache 
migraine 
Types of 
treatment 
biofeedback, 
relaxation, 
bio/relax. 
Appendix B : Summary of Reviews 
Number of 
studies 
analyzed 
47 
Quantitative 
(yes/no) 
yes 
Type of change Other variables 
score used considered 
pre-post change gender, 
scores age, 
quality, 
duration of 
treatment. 
Major findings 
All three 
treatments show 
similar 
effectiveness 
rates . 
Outcome does not 
vary by gender or 
age 
Inconclusive on 
duration of 
treatment. 
(table continues) 
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N 
Authors (date) 
Bogaards & ter Kuile 
(1994) 
Type of 
headache 
tension 
headache 
Types of 
treatment 
EMO 
Biofeedback, 
Relaxation, 
Bio/relax, 
Cognitive 
Therapy. 
Pharmaco-
logical 
( amitriptyline, 
diazepam, 
ibuprofen, 
asprin, 
aceta-
minophen, 
naproxen-
sodiwn, 
clomipramine, 
doxepin, 
trzanidine) 
Placebo, 
Control. 
Nwnber of 
studies 
analyzed 
78 
Quantitative 
(yes/no) 
yes 
Type of change 
score used 
pre-post 
treatment scores 
Other variables 
considered 
treatment setting, 
duration of 
treatment, therapist 
training, 
age, 
duration of 
headache, 
gender, 
method of subject 
recruitment, 
nwnber of subjects, 
drop outs, 
outcome measure, 
diagnostic criteria, 
year of publication, 
internal validity. 
Major findings 
All non-
pharmacological 
treatments are 
superior to 
pharmacological 
treatments for 
tension headache 
(when 
pharmacological 
treatments are 
pooled). 
Outcomes vary by 
type of outcome 
measure used 
(headache diary 
versus other 
methods. 
Studies that 
examine short 
duration 
treatments result 
in higher 
percentages of 
improvement. 
Age is related to 
poor outcome. 
Gender and 
method of 
recruitment are 
not related to 
outcome. 
(table continues) ...... 
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Number of 
Type of Types of studies 
Authors (date) headache treatment analyzed 
Compas, Haag, Keefe, migraine Cognitive 21 
Leintenberg, & Williams therapy, 
(1998) Cog-beh 
therapy, 
biofeedback, 
relaxation. 
Duke University & The migraine Relaxation 29 
Center for Clinical therapy, 
Health Policy Research thermal 
(1999a) biofeedback, 
EMG 
biofeedback, 
cognitive-
behavioral 
therapy, 
acupuncture, 
TENS, spinal 
manipul-ation, 
hyperbaric 
oxygen. 
Quantitative Type of change Other variables 
(yes/no) score used considered 
no pre- post none 
improvement 
yes Standard-ed none 
effect 
sizes 
percent 
improved 
· Major findings 
All biofeedback 
and relaxation 
treatments have 
similar effect 
rates. 
There is limited 
·evidence for 
Cognitive 
therapies, but 
what is available 
appears 
promising. 
Thermal 
biofeedback plus 
relaxation 
therapy, 
relaxation 
training, and 
EMG biofeedback 
are al modestly 
effective in 
treating migraine. 
(table continues) 
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Number of 
Type of Types of studies Quantitative Type of change Other variables 
Authors (date) headache treatment analyzed (yes/no) score used considered Major findings 
Duke University & The migraine (Category-see 258 yes Standardized none Propranolol, 
Center for Clinical detailed list at effect sizes, timinolol, 
Health Policy Research the end of the divalproex 
(1999a) table) Odds ratios sodium, 
alpha-2- amitriptyline, 
agonsits, flunarizine, and 
anitconvul- pizotifen all have 
sants, anti- effect sizes 
depressants, between .52 and 
beta-blockers, .93. Participant 
calcium drop outs are a 
antagonists, major issue in 
ergots, pharmacological 
NSAIDS, research. 
hormonal 
treatments, and 
seritonin-ergic 
drugs. 
Flor, Fydrich, & Turk back pain no headache 65 yes Standardized age, Outcome varies 
(1992) treatments effect sizes gender, by age, marital 
examined pain duration, status, education 
% working, 'level, SES, 
% married, employment stats, 
years in school, compensation and 
litigation, medication use. 
compensation, 
surgery, 
long/short term. 
(table continues) 
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Authors (date) 
Holroyd & Penzien 
(1985) 
Type of 
headache 
tension and 
client 
variables 
Types of 
treatment 
EMG 
Biofeedback, 
Relaxation, 
Combo 
treatment, 
no treatment, 
Number of 
studies 
analyzed 
37 
Quantitative 
(yes/no) 
yes 
Type of change 
score used 
Pre-post change 
scores ( only 
from studies 
using headache 
diaries) 
Other variables 
considered 
# of subjects, 
dropout, 
gender, 
age, 
source of client, 
duration of 
treatment, 
transfer training, 
assignment to 
groups, 
internal validity, 
diagnostic criteria. 
Major findings 
Outcome does not 
vary by research 
design . 
Outcome varies 
by age, year of 
publication, 
gender, and 
dropout rate. 
All treatments 
have similar 
effectiveness 
rates. 
(table continues) 
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Number of 
Type of Types of studies Quantitative 
Authors (date) headache treatment analyzed (yes/no) 
Holroyd & Penzien migraine Propranonol, 60 yes 
(1990) bio/relax , 
no treatment , 
placebo. 
Holroyd & Penzien migraine Propranonol, 73 yes 
(1990) relaxation / 
biofeedback , 
placebo . 
Type of change Other variables 
score used considered 
headache index Outcome measure . 
pre-post scores 
headache index number of subjects , 
gender, 
pre-post age, 
improvement outcome measure, 
score dropout rate, 
migraine diagnosis, 
Propranonol dose, 
dropout due to side 
effects, 
blind to condition, 
# ofbio sessions, 
transfer training. 
Major findings 
43% 
improvement for 
both active 
treatments. 
Treatment effects 
vary by outcome 
measure . 
Similar 
improvement 
rates for 
biofeedback/relax 
ation training and 
Propranonol. 
Results vary by 
type of outcome 
measure (daily 
recording versus 
global estimates). 
(table continues) 
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~ 
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Number of 
Type of Types of studies Quantitative Type of change Other variables 
Authors (date) headache treatment analyzed (yes/no) score used considered Major findings 
Holroyd, Penzien, & migraine Propranonol. 53 yes pre-post scores, # of subjects, Conservative 
Cordingley (1991) placebo- age, estimates of 
treatment migraine diagnosis, Propranonol 
change score chronicity , treatment effects 
dropout rate, indicate a 44% 
drop out due to side reduction in 
effects, frequency, 
dose, duration, and 
blind to condition. intensity of 
migraine 
headache. 
Dose issues do 
not effect 
outcome. 
Type of outcome 
measure do effect 
treatment 
outcome 
(headache diary 
versus global 
measurements) 
Lander (1980) general pain No headache 42 no none patient variables, Research on pain 
treatments differences in management is 
considered. sample, selection, poor due to 
gender, methodological 
SES, flaws and a 
age, failure to include 
duration of pain the referenced 
variables. 
(table continues) ~ 00 
Number of 
Type of Types of studies Quantitative Type of change Other variables 
Authors (date) headache treatment analyzed (yes/no) score used considered Major findings 
Onghena & Van tension amitriptyline, 39 yes Standardized dosage level, Antidepressant 
Houdenhove (1992) headache, phenelzine, effect size depression medications 
migraine, irniprarnine, diagnosis, induce an 
chronic doxepin, # of patients, analgesic effect. 
pain. dibenzepine, gender, 
clomipramine, mean age, The effect 
femoxetine, mean duration of decreases pain in 
dothiepin, pain, all of the pain 
mianserin, quality, conditions tested . 
trazodone, use of analgesics. 
Malone & Strube (1988) non- atogenic 109 yes standardized type of pain Outcomes vary by 
Chronic biofeedback, effect size, (back, neck, cancer, how researchers 
pain cognitive, percentage dental, iatrogenic, calculate change 
hypnosis, improved (pre- join, migraine , ( effect size or % 
no treatment, post) mixed group, mixed improved) . 
operant, headache, tension 
pill placebo , headache, other) . Effect size is 
relaxation, more sensitive . 
wait list. 
Treatments are 
uniform in 
outcome across 
pain categories. 
(table continues) 
-
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Treatments examined in Duke University and the Center for Clinical Health Policy Research. 
Alpha-2-agonistsis 
clonidine, guanfacine. 
Anticonvulsants 
divalproex sodium, carbamazepine, clonazepam, gabapentin. 
Antidepressants 
amitriptyline, clomipramine, femoxetine, fluoxetine, fluvoxamine, mianserin, opipramol. 
Beta-blockers 
propranolol, metoprolol acebutolol, alprenolol, atenolol, bisoprolol, nadolol, oxprenolol, pindolol, practolol, timolol. 
Calcium antagonists 
cyclandelate, flunarizine, nicardipine, nifedipine, nimodipine, verapamil. 
Ergots 
dihydroergotamine, dihydroergokrptine, egrotamine, Cafergot 
Methysergide; nonsteroidal anti-inflammatory drugs (NSAIDS) 
aspirin, fenoprefen, flurbiprofen, indobufen, idomethacin, ketoprefen, lomoxicam, mefamic acid, naproxen, naproexn sodium, 
tolfenamic acid. 
Other Serotoninergic Drugs 
pizotifen, lisuride, oxitriptan, iprazochrome, tropisetron. 
Other Treatments 
hormonal preparations and feverfew. 
..... 
v, 
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Appendix C: Excluded Articles 
Table C l  
Propranolol Excluded Articles 
Authors (date) Reason for exclusion 
Al Qassab & Findley, 1992 Insufficient data 
Baldrati et al., 1983 Insufficient data 
Behan & Reid, 1980 Insufficient data 
Bordini, Arruda, Ciciarelli, & Speciali, 1997 Insufficient data 
Carroll, Reidy, Savundra, Cleave, & McAinsh, 1990 Insufficient data 
Cortelli et al., 1985 Insufficient data 
Diamond, Kudrow, Stevens, & Shapiro, 1982 Insufficient data 
Diener et al., 2002 Insufficient data 
Gawel, Kreeft, Nelson, Simard, & Arnott, 1992 Insufficient data 
Gerber, Diener, Scholz, & Niederberger, 1991 Insufficient data 
Gerber et al., 1995 Insufficient data 
Holroyd, Penzien, Rokicki, & Cordingley, 1992 Brief report-insufficient data 
Kass & Nestvold, 1980 Insufficient data 
Leahey, Neill, Varma & Shanks, 1980 Results on blood pressure 
Malvea, Gwon, & Graham, 1973 Insufficient data 
Olerud, Gustavsson, & Furberg, 1986 Insufficient data-no control 
group 
Olsson et al., 1984 Insufficient data-no control 
group 
Palferman, Gibberd, & Simmonds, 1983 Insufficient data 
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(table continues) 
Authors (date) 
Pascaul, Polo, & Berciano, 1989 
Raskin & Schwartz, 1980 
Scholz, Gerber, Billie, Niederberger, & Fahrner, 
1987 
Shimell, Fritz, & Levien, 1989 
Solomon, 1986 
Stensrud & Sjaastad, 1980a 
Stensrud & Sjaastad, 1980b 
Sudilovsky et al., 1987 
Wobeer, Wober-Biingoi, Koch, & Wessely, 1991 
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Reason for exclusion 
Insufficient data 
Retrospective study 
Report results for plasma levels 
only 
Insufficient data 
Abstract-unusable statistics 
Insufficient data 
Duplicate of above 
Cost effectiveness study 
Long term results after 
discontinuation of treatment. 
Table C2 
Flunarizine Excluded Articles 
Amery, 1983 
Amery et al., 1981 
Angoli et al., 1991 
Andersson, 1985 
Baker, 1987 
Authors (date) 
Bassi, Brunati, Rapuzzi, Alberti, & Mangoni, 1992 
Bonuso et al., 1986 
Centonze et al., 1983 
Centonze, Magrone, & Vino, 1990 
Cerbo et al., 1986 
D'Amato, D'Amato , Alfano, Giordano, & Marmo, 
1990 
Diamond & Schenbaurn, 1983 
Germain & Neuron, 1990 
Grotemeyer, Schlake, & Husstedt,.1987 
Grotemeyer, Schlake, & Husstedt, 1989 
Hansen, Sorensen, & Olesen, 1989 
Holmes, Brogeden, Heel, Speight, & Avery, 1984 
Leandri, Parodi, Bacigalupo, & Farinini, 1985 
Louis, 1987 
Louis and Spierings, 1982 
Reason for exclusion 
Reviews others data 
Reviews pharmacology 
Comparison-provided 
insufficient data 
Abstract, insufficient data 
Abstract, insufficient data 
Insufficient data 
Migraines induced 
Insufficient data 
Insufficient data 
Insufficient data 
Insufficient data 
Insufficient data 
Insufficient data 
Insufficient data 
Insufficient data 
Insufficient data 
Review 
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Data artificially dichotomized 
Insufficient data 
Insufficient data 
(table continues) 
Authors (date) 
Martinez-Lage, 1988 
Mendenopoulos, Manafi, Logothetis, & 
Bostantjopoulou, 1985 
Nappi et al., 1987 
Pfaffenrath, Oestreich, & Haase, 1990 
Schmidt & Oestreich, 1991 
Sorenson and the Danish Migraine Study Group, 1989 
Soyka & Oestreich, 1987 
Soyka, Taneri, Oestreich, & Schmidt, 1988 
Spierings & Messinger, 1988 
Sterdo et al., 1986 
Wauquier, Ashton, & Marranes, 1985 
Reason for exclusion 
Included large numbers of 
dhildren 
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Duplicate ofMentenopoulos, 
Manafi, Logothetis, & 
Bostantjopoulou, 1985 
Comparison-
provides insufficient data 
Focus on acute treatment 
Clinical case review 
Comparison-
provides insufficient data 
Insufficient data 
Focus on acute treatment 
Reviews others data 
Comparison-
provides insufficient data 
Focused on animal models 
Table C3 
Excluded Divalpoex Sodium Articles 
Authors (dates) 
Hering & Kuritzky, 1992 
Klapper, 1997 
Mathew & Ali, 1991 
Mitsikostas & Polychronidis, 1997 
Silberstein & Collins, 1999 
Sorensen, 1988 
Reason for exclusion 
Insufficient data 
Insufficient data 
Insufficient data 
Insufficient data 
Insufficient data 
Insufficient data 
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Table C4 
Nonpharmacologica/ Excluded Studies 
Authors (dates) Reason for exclusion 
Alder & Alder, 1976 Inappropriate design 
Anderson, Basker, & Dalton, 1975 Treatment not included 
Andrasik, Blanchard, et al., 1984 Insufficient data 
Andrasik, Pallmeyer, Blanchard, & Attanasio, Not outcome based 
1984 
Andreychuk & Skriver, 1975 Insufficient data 
Billings, Thomas, Rapp, Reyes, & Leith, 1984 Retrospective 
Blanchard, 1987 Chronic headache 
Blanchard, Andrasik, Evans, et al., 1985c Insufficient data 
Blanchard, Andrasik, Neff, Arena, et al., 1982 Inappropriate design 
Blanchard, Andrasik, Neff, & Appelbaum, 1985 Inappropriate design 
Blanchard, Andrasik, Neff, T eders, et al., 1982 Inappropriate design 
Blanchard et al., 1987 Follow-up 
Blanchard, Jaccard, Andrasik, Guarnieri, & Focus on expenses 
Jurish, 1985 
Brown, 1984 Treatment not included 
Cohen, McArthur, & Rickles, 1980 Insufficient data 
Daly, Donn, Galliher, & Zimmerman, 983 Insufficient data 
Diamond & Montrose, 1983 Retrospective 
Fahrion, 1977 Insufficient data 
Feuerstein & Adams, 1977 Single subject 
French, Gauthier, Roberge, Bouchard, & Nowen, Insufficient data 
1997 
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(table continues) 
Authors (dates) 
Friedman & Taub, 1984 
Ford , Stroebel , Strong, & Szarek, 1983 
Gainer, 1978 
Gallagher & Warner, 1984 
Gamble & Elder, 1983 
Gauthier, Bois, Allaire, & Drolet , 1981 
Gauthier & Carrier, 1991 
Gauthier, Doyon, Lacroix , & Drolet , 1983 
Gauthier , Fradet , & Roberge , 1988 
Gauthier, Ivers, & Carrier , 1996 
Hart, 1984 
Holroyd et al., 1989 
Howard , Reardon , & Tosi, 1982 
Ilacqua , 1994 
Janssen & Neutgens , 1986 
Kabela, Blanchard, Appelbaum, & Nicholson 
(1989) 
Kewrnan & Roberts , 1980) 
Lacroix et al., 1983 
Lisspers & Ost, 1990 
Mizener, Thomas, & Billings, 1988 
Morrill & Blanchard, 1989 
Nicholson & Blanchard, 1993 
Reason for exclusion 
Insufficient data 
Insufficient data 
Single subject 
Insufficient data 
Insufficient data 
Insufficient data 
Follow-up 
Treatment not included 
Insufficient data 
Review 
Insufficient data 
Used only successfully treated 
Single subject 
Insufficient data-
no frequency data 
Insufficient data 
Too few migraine subjects 
Insufficient data 
Insufficient data 
Follow-up 
Insufficient data-
no frequency data 
Insufficient data-
focus on temperature 
Too few migraine subjects 
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(table continues) 
Olson, 1988 
Reading, 1984 
Reich, 1989 
Authors (dates) 
Sargent, Walters, & Green, 1973 
Smith, 1987 
Sorbi & Tellegen, 1984 
Sorbi & Tellegen, 1986 
Sovak, Kunzel, Stembach, & Dalessio, 1981 
Turin & Johnson, 197 5 
Werbach & Sandweiss, 1978 
Reason for exclusion 
Follow-up on mixed headache 
Insufficient data 
Insufficient data 
Insufficient data 
Insufficient data 
Insufficient data 
Treatment not included 
Insufficient data 
Too few subjects 
Insufficient data 
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Table Dl 
Coding Sheet 
Study ID# 
Headache type 
!=migraine 
2=mixed 
}=vascular 
treatment type 
l =pharrn 
2=nonpharm 
subgroup 
l=Propranonol 
2=flunarizine 
3=Divalproex Sodium 
4=TBF 
5=Relaxation 
6=EMG 
7=Cog therapies 
% sample female 
Type of headache record 
( I =daily diary 
2=client estimation 
3=researcher estimate). 
Treatment length in weeks 
Comparitive group 
!=placebo 
2=control 
}=baseline-control 
4=baseline comparison 
Study type 
!=parallel 
2=crossover 
Year of study 
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Appendix D: Data Collection Materials 
(table continues) 
Study ID# 
# of months between 
treatment and follow-up 
# of days drug wash out 
period 
# of sessions 2 
Total mortality rate 
Data type 
I =continuous 
2=binary 
Stats-mean 
sd, s, ci 
t, F, Z, r 
pre-post 
within 
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Table D2 
·Data Page 
Sp= 
(nl- l)sl 2 + (n2- l)s2 2 
nl + n2- 2 
n2= 
s2(sqr)= 
nl = 
sl(sqr)= 
Sp= 
~~~~~~~~~~~~~ 
N 
Mean 
F 
-
T 
P(exact) 
paired T 
pre 
post 
Binary 
%Success 
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Appendix E: Quality of Study Rating Sheets 
Question Response Score 
1 Was the study described as randomized (this yes 1 
includes the use of words such as randomly, 
random and randomization) no 0 
la If the method of generating the sequences of Not described 0 
randomization was described, was it adequate 
(table of random numbers, computer-generated, Adequate 1 
coin tossing etc.) or Inadequate (allocated 
alternately, according to date of birth , hospital Inadequate - 1 
number, etc) 
2 Was the study described as double blind? Yes 1 
No 0 
2a If the method of blinding was described, was it Not Described 0 
adequate (identical placebo , active placebo, Adequate 1 
dummy etc) or inadequate (comparison of tablet 
vs. injection with no double dummy) Inadequate -1 
3 Was there a description of withdrawals and Yes 1 
dropouts No 0 
Score= 
Note. For sections la and 2a a study automatically receives a zero in these sections if the 
previous section (lor 2) is a zero. The scores of(-1) are only used when the study scored 
a (1) on the previous section. For example, a study that specifically states that it is 
randomized but then states it used alternate allocation would receive a score of"l" in 
section (1) and a score of a "-1" section (la). Therefore, no study can receive a score of 
less than zero. Alternatively, a study that specifically states that it is a double blind study 
but does not describe how double blinding was achieved would receive a score of"l" in 
section (2) and a score of" O" in section (2a). 
Figure El . Quality of study instrument (Jadad et al., 1996). 
NECESSARY CONDITIONS 
1 point O points 
Measurement of Headaches 
Type of Control 
Journal/Likert Scale __ Self Report 
_ _ Placebo/Comparison Baseline 
OTHER CONDITIONS 
Cross-Over Design 
Run-in/Wash Out Period 
Baseline/follow-up 
Multiple Setting 
Compared to another 
Active tx. 
Other Meds Controlled 
Compliance Measured/ 
Homepractice 
Yes= l 
3=Great= All Necessary conditions and 3 other 
No=O 
2=Good = at least 1 of Necessary conditions and 3 other or 2 Necessary and 2 other 
1 =Okay = no Necessary conditions or 1 Necessary condition and less than 3 other 
Nee. Cond = + = 
Figure E2. Headache literature quality rating . 
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Appendix F: Formulas Used in Calculations of Effect Size 
All calculations were performed with the aide of Meta-Stat ® a statistical software 
program developed by Rudner, Glass, Evart, and Emery (2000). 
Calculating an unbiased standardized mean difference ( d) 
Equation 1 
g = X exp- X cont/ SDpooied 
Equation 2 
d= g(l-(3/4m-1)) 
Example 1 
So, if an article presents and experimental mean of3.69 (N = 80) 
and a control mean of2.54 (N = 80). A pooled standard deviation 
of 3.65. Results are as follows, 
g = 3.69 - 2.54/3.65 = .31 
d = .31 (1-(3/4(158)-1) 
d = .31 (1-(3/631) 
d = .308 
Calculating an effect size from Parametric Gain Scores 
Equation 3 
Xepost - X epre d=-----
O exp re 
Example 2 
X con tpost - X con tpre 
O contp re 
So if the article presents experimental treatment group data as 
Pre Mean= 4.12, SD = 3.7, Post Mean 1.57, SD= 1.35 
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and control group data as Pre Mean = 3.4, SD= 2.98, Post Mean 2.72, SD 
= 1.78 
The calculation would be as follows 
d = (4.12-1.57)/3.7 - (3.4-2.72)/3.4 
d = 2.55/3 .7 - .68/3.4 
d = .689 - .2 
d = .489 
Calculating an effect size as a paired comparison t-test 
Equation4 
--fii d = D-- Where D is the mean difference between the observed pairs. 
t 
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Example 3 
So, for an article that presents a paired t score of2.114, a mean 
difference score of .2617, with 30 paired observations, the 
calculation would be 
d =.2617-Jw I 2.114 
d = .678 
Calculating an effect size from r 
Equation 5 
d-
- g 
See formula use in calculations below for p value and F value conversions. 
The results from these formulas are plugged into the formula to calculate an effect size 
for r. 
Calculating an r from an F-statistic 
Equation 6 
r = /Fif Where df is the error term degree of freedom and there is only 1 v~ 
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degree of freedom in the interaction term. 
Example 4 
So, if the F value is given as 3 .175 with 18 degrees of freedom in 
the denominator , the calculation would be as follows 
3.175 
r= 3.175 - 18 
r = .462 
Using the formula for an effect size conversion for r 
d= 
d = 1.04 
4(.462) 2 
1- (.462) 2 
Calculating an r from an exact p value 
Equation 7 
Equation 8 
[ 
(2.515517)(.802853a)(.010328a 2 ) ] 
z- a 
- 1- (1.432788a)(.189269a 2 )(.001308a 3 ) 
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Then insert into the formula for a z value 
Example 5 
So, if an article presented a p value of .021 (N=60) , then the 
calculation would be as follows 
a = -J2267.57 
a = 7.7265 
z = 7.7265[ ___ (2_.5_1_55_1_7_)(_.8_02_8_5_3 _x _7._72_6_5_)(_.0_l 0_3_2_8_x _5_9._69_8_) __ ] 
1- (1.432788 x 7.7265)(.189269 x 59.698)(.001308 x 461.262) 
z = 7.7265 (9.621/-74.41) 
z=.99 
Then, calculating an r from a z value 
r = .J.99 2 I 60 
r = .127 
Using the formula for an effect size from r 
d= 
4(.127) 2 
1- (.127) 2 
d = .256 
Calculating an effect size for a cross-over study 
Equation 9. 
Xe-X 
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d = where r ec is the correlation between the experimental and 
SDc-JI - r ec 2 
control. For cross-over studies the correlation is between pre-post because 
experimental and control subjects are the same. 
Example 6. 
If the lowest correlation between pre-post measures is reported to 
be or calculated to be .45, experimental mean of3.69 and a control 
mean of2.54, A pooled standard deviation of 3.65. (Same numbers 
from Example 1.) Results are as follows, 
3.69- 254 
d=--=== 
3.65-J 1- .452 
d = 1.15/3.65 (.89) 
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d = 1.15/3.25 
d = .35 ( to note difference adding correlation makes 
compare to effect size calculation from Example 1. 
where d = .308) 
Calculating pooled standard deviations 
Equation 10 
Sp= 
(nl - l)sl 2 + (n2 - l)s2 2 
nI + n2 - 2 
Example 7 
So , if a article presents with a SD for a treatment group of3.44 (N 
= 80) and a SD for a control group of3 .85 ( N = 80), the 
calculation would be 
Sp= 
79(3.44)2 + 79(3.85)2 
79+ 79- 2 
Sp= 3.65 
Calculating an Odds Ratio 
Equation 11 
ad 
OR = be where a = positive outcomes for experimental group , b = positive 
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outcomes for control, c = negative outcomes for the experimental group, and d = negative 
outcomes from the control groups. a+b+c + d = N. 
Example 8. 
If an article presents the information that out of 30 experimental 
subjects 22 achieved at least a 50% reduction in symptoms and 10 
out of 30 in the control group achieved the same criteria, the 
calculation would be as follows. 
a = 22 , b = 10, c = 8, d = 20 
OR =(22 )(20)/(10)(8) 
OR = 5.5 
Calculating Cochrane's Q 
Equation 12. 
Qw = L w(Y,: - µ)2 where w= the inverse of the variance (or weight) , Yi = 
the effect size of each trial , and µ = the overall effect estimated from the meta-
analysis. 
Example 9. 
If a meta-analysis is being performed on three studies and effect 
sizes have been calculated on continuous data the following 
information would be available. 
Study 1 
Study 2 
Study 3 
d = .40 
variance) = 9. 5 
d = .51 
d = .51 
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variance = .11 weight (inverse of the 
variance = .10 weight (inverse of the 
variance) = 9 .3 
variance = .17 weight (inverse of the 
variance) = 5. 8 
If these numbers used to calculate an overall effect size with the 
REM model (using Meta-Analysis® computer program) the 
population effect size estimate is found to be .47. Using this as the 
population estimate of effect a Cochrane's Q can be calculated . 
Qw ::: 9.5(.40-.47) 2 + 9.3(.51-.47) 2 + 5.8(.51-.47) 2 
Qw = 9.5(.0049) + 9.3(.0016)+5.8(.0016) 
Qlv =.069 
A very small Cochrane's Q which indicates very little variation 
between studies. 
Table GI 
Appendix G: Regression Analyses and Correlation 
Results for Propranolol 
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Summary of Regression Analysis for Variables Predicting Treatment Outcome Results 
for Propranolol 
Variable B SEB p 
Entered 
Study type .483 .172 .011 
Excluded B I p 
Comparison group .28 .138 .892 
Control group type .188 .999 .330 
Length ofTx -.002 -.008 .994 
Outcome measure -.263 -1.453 .162 
Quality score (Jadad) -.224 -1.196 .246 
Quality rating -.266 -1.431 .168 
Mortality rate -.072 -.378 .710 
Percent female .036 .189 .852 
Publication year .188 .883 .388 
Note. R2 =.273, F= 7.89. 
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Table G2 
Correlation Between Variables and Unbiased Effect Sizes for Propranolol 
Correlation (r) with Correlation (r) with 
Variable unbiased effect size Variable unbiased effect size 
Comparison group -.42 Quality rating -.367 
Control group type .080 Mortality rate -.058 
Length ofTx -.272 Percent female -.045 
Outcome measure -.257 Publication year .109 
Quality score( Jadad) -.308 Study type .514** 
Note. ** Correlation is significant at that 0.01 level (2-tailed). 
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Appendix H: Regression Analyses and Correlation 
Results for Flunarizine 
Table HI 
Summary of Regression Ana lysis for Variables Predicting Treatment Outcome Results 
for Flunarizine 
Variable B SEB p 
Entered 
Treatment length .772 .014 .001 
Excluded B t p 
Comparison group -.231 -.232 .243 
Control group type .008 -.037 .971 
Outcome measure -.033 -.167 .871 
Quality score (Jadad) .191 1.019 .330 
Quality rating .320 1.887 .086 
Mortality rate -.130 -.624 .545 
Percent female -299 -1.699 .117 
Publication year -.533 -3.037 .011 
Study type .220 1.165 .269 
Note. R2 =.587, F= 17.074. 
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Table H2 
Correlation Between Variables and Unbiased Effect Sizes for Flunarizine 
Correlation (r) with Correlation (r) with 
Variable unbiased effect size Variable unbiased effect siz 
Comparison group -.403 Quality rating -.211 
Control group type .303 Mortality rate -.417 
Length of Tx. .733** Percent female -.135 
Outcome measure -.182 Publication year .082 . 
Quality score(Jadad) .061 Study type .399 
Not e. ** Correlation is significant at that 0.01 level (2-tailed). 
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Appendix I: Regression Analyses and Correlation 
Results for Divalproex Sodium 
None of the variables met the inclusionary criteria for a stepwise regression 
(F < .05) thus variables were forced in through the enter method to obtain values. 
Table II 
Summary of Regression Analysis for Variables Predicting Treatment Outcome Results 
for Divalproex Sodium 
Variable B SEB p 
Entered 
None 
Excluded B t p 
Comparison group NIA NIA NIA 
Control group NIA NIA NIA 
Quality score (Jadad) -.234 -.627 .564 
Quality rating -.332 -.863 .437 
Outcome measure NIA NIA NIA 
Mortality rate -.356 -1.150 .314 
Percent female -.452 -1.376 .241 
Publication year -.037 -.106 .921 
Treatment length 4.071 .646 .553 
Study type .324 1.013 .368 
Note. R2 =1.00. Comparison group, control group, and outcome measure deleted from 
regression because they were constants or nearly constants could not be computed. 
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Table 12 
Correlation Between Variables and Unbiased Effect Sizes for Divalproex Sodium 
Correlation (r) with Correlation (r) with 
Variable unbiased effect size Variable unbiased effect size 
Comparison group .72 Quality rating -.631 
Control group type -.72 Mortality rate -.168 
Length ofTx -.223 Percent female -.698 / 
Outcome measure NIA Publication year .165 
Quality score -.515 Study type .117 
(Jadad) 
Note. ** Correlation is significant at that 0.01 level (2-tailed). Outcome measure deleted 
because it was a constant. 
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Appendix ]:Regression Analyses and Correlation 
Results for Thermal Biofeedback 
None of the variables met the inclusionary criteria for a stepwise regression 
(F < .05) thus variables were forced in through the enter method to obtain values. 
Table JI 
Summary of Regression Analysis for Variables Predicting Treatment Outcome Results 
for Thermal Biofeedback 
Variable B SEB p 
Entered 
None 
Excluded B t p 
Comparison group -.176 -3.920 .030 
Control group type 2.641 .705 .532 
Outcome measure -.233 -2.210 .114 
Quality score -.686 -3.012 .057 
(Jadad) 
Quality rating -6.23 -.310 .777 
Mortality rate 3.446 -2.357 .100 
Percent female 8.011 1.650 .198 
Publication year 3.355 .344 .754 
Treatment length 8.341 .035 .974 
Study type NIA NIA NIA 
Note. R2 =.928, F = 3.876. Variable study type removed because is was a constant. 
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Table 12 
Correlation Between Variables and Unbiased Effect Sizes for Thermal Biofeedback 
Correlation (r) with Correlation (r) with 
Variable unbiased effect size Variable unbiased effect size 
Comparison group -.072 Quality rating -.249 
Control group type .495 Mortality rate -.222 
Length of Tx. .159 Percent female -.440 
Outcome measure -.411 Publication year .221 
Quality score -.241 Study type NIA 
(Jadad) 
Note. Study type removed because it was a constant. 
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Appendix K: Correlation Tables for Relaxation Therapy 
Table Kl 
Correlations Between Variables and Unbiased Effect Sizes for Relaxation Therapy 
Correlation (r) with Correlation (r) with 
Variable unbiased effect size Variable unbiased effect size 
Comparison group -.603 Quality rating -.698 
Control group type NIA Mortality rate .159 
Length ofTx. .459 Percent female .057 
Outcome Measure .603 Publication year -.389 
Quality score -.698 Study type NIA 
(Jadad) 
Note . Control group and study type deleted because they are constants. 
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Appendix L: Post-Hoc Multiple Comparisons 
with Bonferroni Corrections 
Table LI 
Post-Hoc Comparisons of Treatments for Continuous Effect Sizes 
Standard error 
Treatments compared t of the difference p value 
Propranolol vs. Flunarizine 0.000 0.023 1.000 
Propranolol vs. Thermal Bio. 3.113 0.026 0.008 
Propranolol vs. Relaxation 1.452 0.048 0.157 
Propranolol vs. Thermal+ Cog. 0.760 0.053 0.453 
Flunarizine vs. Thermal Bio. 2.522 0.032 0.017 
Flunairizne vs. Relaxation 1.175 0.060 0.256 
Flunarizine vs. Thermal+ Cog. 0.619 0.065 0.544 
Thermal vs. Relaxation 2.238 0.067 0.038 
Thermal vs. Thermal + Cog. 1.6215 0.074 0.123 
Relax vs. Thermal + Cog. 0.196 0.153 0.852 
Note. Bonferroni Correction criteria is p < .005. ANOV AF = 2.9024, p = 0 .0297. 
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Table L2 
Post-Hoc Bonferroni Comparisons of Treatments for Continuous Effect Sizes 
Standard error 
Treatments compared t of the difference p value 
Propranolol vs. Flunarizine 0.060 0.148 0.562 
Propranolol vs. Divalproex Sodium 0.745 0.094 0.475 
Propranolol vs. Thermal Bio. 0.000 0.019 1.000 
Propranolol vs. EMG Bio. 3.414 0.261 0.014 
Propranolol vs.EMG + Thermal Bio. 2.384 0.191 0.048 
Flunarizine vs. Divalproex Sodium 0.745 0.215 0.483 
Flunarizine vs. Thermal Bio. 0.603 0.149 0.565 
Flunarizine vs. EMG Bio. 1.946 0.503 0.1468 
Flunarizine vs. EMG + Thermal Bio. 1.012 0.379 0.368 
Divalproex Sodium vs. Thermal Bio. 0.210 0.095 0.837 
Divalproex Sodium vs. EMG Bio. 2.682 0.339 0.043 
Divalproex Sodium vs. 1.737 0.259 0.132 
EMG + Thermal Bio. 
Thermal Bio. vs. EMG Bio. 3.402 0.262 0.014 
Thermal Bio. vs EMG + Thermal Bio. 2.375 0.198 0.049 
EMG Bio. vs. EMG + Thermal Bio.S 2.407 0.565 0.095 
Note. Bonferroni correction criteria is p < .003. ANOVA F = 3.177, p = 0 .314. 
184 
VITA 
Kristi Lowe Stewart 
School Address: 1492 East Spring Lane #317 
Salt Lake City, Utah, 84117 
(801) 277-5271 
Department of Psychology 
2810 Old Main Hill 
Logan, Utah 84322-2810 (801) 412-2563 
Education 
PhD Internship Salt Lake City Veterans Administration Medical Center 
MS 
BS 
Medical Psychology/Substance Abuse/ Outpatient Mental Health 
Full APA Accreditation 
Utah State University, Logan, Utah, June, 1998. 
Clinical/Counseling Psychology 
School Psychology Certified 
Full APA Accreditation 
University of Utah, June 1994 
Major : Psychology 
Clinical Experience and Employment 
Adult Psychology 
200 I -present 
200 I-present 
200 I -present 
1999-2000 
1999 
1996 - 1999 
Therapist, Jordan Family Education Center, Midvale, Utah. 
Family and couples intervention. 
Instructor, Jordan Family Education Center. Midvale , Utah. 
Calming the Storm, Anger management for adults . 
Psychology Resident, University of Utah Neuropsychiatric Institute. 
PRN intervention Child/ Adolescent/Family/ Adult. 
Therapist, Veterans Administration Hospital, Salt Lake City, Utah. 
Individual/Couples therapy, Inpatient/Outpatient, and Substance Abuse. Focus on 
individuals who are substance abuses with personality disorders and/or trauma histories 
Therapist, Bear River Mental Health, Logan, Utah. 
Individual and child assessment and treatment. General mental health, low income and 
medicaid/medicare clients. 
Therapist, Psychology Community Clinic, Utah State University. 
Individual, couple, family and child therapy. Focus on general mental health and 
personality disorders. 
185 
1997 - 1999 Therapist, Student Counseling Center, Utah State University. 
Individual assessment and treatment of students . General mental health and crisis work. 
Behavioral Medicine/Substance Abuse 
200 I -present 
2000-2001 
1999 - 2000 
Psychology Resident, University of Utah Neuropsychiatric Institute. 
PRN intervention Child/ Adolescent/Family/ Adult. 
Psychology Resident, University of Utah Neuropsychiatric Institute. 
Child/ Adolescent/Family/ Adult inpatient hospital: neuorpsychological assessment, 
psychological assessment, intervention, detox, pain management, crisis intervention. 
Psychology Intern, Salt Lake City Veterans Administration Medical Center. 
Medical Psychology Rotation: Neuorpsychological assessment, cardiac transplant and 
presurgical evaluations, pain management, adjustment to illness, competency 
evaluations , rehabilitation, interdisciplinary team member , consultation. 
Inpatient / Outpatient Mental Health and Substance Abuse : Drug and alcohol 
assessment/treatment/detox , inpatient assessment/treatment, PTSD , geriatric 
psychology, adult mental health. 
Child Psychology 
200 I -present 
200 I-present 
200 I -present 
2000-2001 
1997 - 1998 
1996 -1998 
1996 - 1997 
School Psychologist, Jordan School District , Sandy, Utah . 
Assessment and treatment for children under the age of 15. Family/Individual /Group. 
Psychology Resident, University of Utah Neuropsychiatric Institute. 
PRN intervention Child/ Adolescent/Family/ Adult. 
Therapist, Jordan Family Education Center, Midvale, Utah . 
Family and couples intervention . 
Psychology Resident, University of Utah Neuropsychiatric Institute. 
Child/ Adolescent/Family/ Adult inpatient hospital: neuorpsychological assessment, 
psychological assessment, intervention, crisis intervention .. 
Child Therapist, Clinical Services , Center for Persons with Disabilities, Utah State 
University. 
Psychological assessment, diagnosis and treatment planning for children and 
adolescents with psychological and behavioral disorders. Group and individual 
Child/Adolescent Therapist, Child Evaluation and Treatment Center, Logan, Utah. 
Treatment, evaluation, and report writing for psychological disorders in children, 
adolescents, and families. 
School Psychology Intern, Davis County School District. Psychological and 
psychoeducational evaluation of elementary and secondary students for classification 
and placement purposes. 
1996 - 1997 
1991-1993 
186 
Child Psychological Assessment, Community Family Partnership, Center for Persons 
with Disabilities, Utah State University. Psychological assessment of children age one 
month to nine years with focus on developmental and intellectual functioning. 
Residential Therapist, The Children's Center , Kearns, Utah. 
Behavioral management , social, emotional, intellectual and physical development 
interventions for children under the age of seven. 
Administrative Experience 
2003-present 
200 I -present 
1999-2000 
1998-1999 
1997-1998 
1996-1997 
1995-1996 
Current 
1997-1998 
Supervisor, Jordan School District, Sandy, Utah . 
Individual supervision of medical students specializing in child psychiatry. 
Supervisor, Jordan School District, Sandy, Utah. 
Individual supervision ofUniversity of Utah practicum students in school psychology. 
Supervisor, Veterans Administration Hospital , Salt Lake City, Utah . 
Individual and group supervision of University of Utah practicum students in the 
Substance Abuse Counseling Program 
Supervisor, Counseling Center, Utah State University . 
Individual and group supervision of a group of undergraduate students in the Peer 
Counselor Program. 
Graduate Student Representative , Utah State University. 
Program development, facilitation of student/faculty issues, and graduate student 
selection committee. 
Graduate Student Representative Faculty Selection Committee, Utah State University. 
Organization of faculty candidate meetings, facilitation of student interviews and mock 
clinical interviews. 
Assistant to the Clinic Director, Psychology Community Clinic, Utah State University. 
Supervision of clinical testing, data base management, community outreach, and 
marketing. 
Research Experience 
Doctoral Dissertation, Utah State University, Pharmacological and Behavioral 
Treatments for Migraine Headaches: A Meta Analysis. Compares the effectiveness of 
available prophylactic treatments for migraine headaches. Supervisor: Kevin S. Masters, 
PhD 
Masters Thesis, Utah State University, Stewart, K.L. Parenting Styles and Internalizing 
Behavioral Problems in Children: An Exploratory Study. Assessment of the 
associations between parenting behaviors and childhood internalizing problems . Thesis 
Chair: Gretchen A. Gimpel Ph.D. 
187 
1997 Research Assistant, Utah State University. A state wide survey of teachers perceptions 
of children with behavioral disorders and learning disabilities. Supervisor: Gretchen A. 
Gimpel Ph.D. 
1991-1994 Research Assistant, University of Utah. Volunteer bias in human sexuality research, 
The effects of erotic films on stereotypical attitudes, MMPI-2 validity studies, and 
Developmental experiences' impact on adult problems solving abilities. Supervisor: 
Donald Strassberg Ph.D. 
Publications 
Strassberg, D & Lowe, K (1995). Volunteer Bias in Human Sexuality Research. The Archives of Sexual 
Behavior , 24, 369-382. 
Presentations 
Lowe Stewart, K.L. (2002). Students with disabilities- accommodating 504 students. Lecture at the Utah 
Counseling Association Conference, Ogden, Utah. 
Stewart, K.L., & Shearer, D.S. (1999). The Impact of Parenting Style on Elementary School Student 
Behavior. Paper Presented at the 1999 annual National Association of School Psychologists, Las 
Vegas Nevada . 
Shearer, D.S. , & Stewart, K.L. (] 998). The relationship between Attention Deficit/Hyperactivity 
Disorder, the TOVA and the ADDES: Implications.for Diagnosis. Presented at the 1988 annual 
Virginia Beach Conference, Virginia Beach, Virginia. 
Stewart, K.L, & Shearer, D.S. (1998). Internalizing symptoms in school-aged children: Stability, 
recognition, and measurement. Presented at the 1998 annual Utah Association of School 
Psychologists Conference, Salt Lake City, Utah. 
Stewart, K.L., & Gimpel, G.A. (1997). Teachers perceptions of Attention Deficit/Hyperactivity Disorder. 
Presented at the 1997 annual National Association of School Psychologists Conference, 
Anehiem, California. 
Stewart, K.L. & Strassberg, D.S. (1994). The use of student populations in human sexuality research. 
Presented at the annual University of Utah Student Research Conference, Salt Lake City, Utah. 
Organizational Activities 
American Psychological Association 
National Association of School Psychologists 
Utah Psychological Association 
Honors 
Psychology Department Fellowship-Utah State University 1997 
Dean 's Honor List, University of Utah- 1993-1994 
Psychology Department Scholarship, University of Utah, 1993-1994 
References 
Scott Hill, PhD, Staff Psychologist, Salt Lake City Veterans Administration Medical Center, Intern 
Supervisor 
500 Foothill Blvd., Salt Lake City, Utah 84148 
(801) 582-1565 x2284 
Kelly Lundberg, PhD, Director of Substance Abuse Services, University of Utah. 
188 
Kay Koellner, PhD, Staff Psychologist, Salt Lake City Veterans Administration Medical Center, Intern 
Supervisor 
500 Foothill Blvd., Salt Lake City, Utah 84148 
(801) 582-1565 x2284 
Kevin Masters, PhD, Associate Professor, Utah State University, Dissertation Chair 
2810 Old Main Hill, Department of Psychology, Logan, Utah 84322-2810 
(435) 797-1463 
